[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 151
1. Lu HZ, Wu YP, Luo W, Han YL, Cai Y, Xu X, Liang J, Liu SM, Wang MR: [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma].
  • OBJECTIVE: The purpose of this study was to investigate the markers which can be used in auxiliary diagnosis of gastric adenocarcinoma (GAC), and their correlation with their clinicopathological features.
  • METHODS: 122 surgical specimens including 99 gastric adenocarcinoma (GAC), 18 adjacent mucosa and 5 distal normal mucosa were collected, and analyzed by in situ hybridization (FISH).
  • RESULTS: The statistical results of FISH and TMA showed that 58.6% of cen17 in tumor tissues were aneuploid, and 45.5% of TP53 and 84.7% of TOPIIalpha were over-expressed in GAC samples, significantly higher than those in non-tumor gastric mucosa (0, 12.1% and 14.1%, respectively) (P = 0.000).
  • The expression of TP53 in non-tumor gastric mucosa with dysplasia was significantly higher than that in the mucosa without dysplasia (P = 0.009).
  • Higher frequency of aneuploidy of cen17 was also observed in the gastric cardia than in pylorus (P < 0.05), while no correlation was found between aneuploidy of cen17 and age, sex of patients, lymph node metastasis, and clinical stage of tumors.
  • CONCLUSION: Detection of aneuploidy of cen17 as well as over-expression of TP53 and TOPIIalpha may be helpful in the diagnosis and prognostic prediction of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aneuploidy. Antigens, Neoplasm / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Stomach Neoplasms. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


2. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S: Multivariate prognostic study on large gastric cancer. J Surg Oncol; 2007 Jul 1;96(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate prognostic study on large gastric cancer.
  • BACKGROUND: Although many authors investigate the prognostic factors of gastric cancer, there are few comprehensive studies on the prognosis of patients with large gastric cancer.
  • The aim of this study was to clarify the prognostic factors of large gastric cancer using multivariate analysis.
  • METHODS: The study included 95 patients who underwent gastrectomy for gastric cancer measuring 10 cm or more in diameter.
  • The 5-year survival rate was influenced by the tumor size, gross type, serosal invasion, extragastric lymph node metastasis, liver metastasis, peritoneal dissemination, stage of disease (I, II vs. III, IV), resection margin, and operative curability (R0 vs. R1, R2).
  • CONCLUSION: In patients with large gastric cancer, independent prognostic factors were serosal invasion, extragastric lymph node metastasis, and liver metastasis.
  • [MeSH-major] Adenocarcinoma / mortality. Gastrectomy / mortality. Lymph Nodes / pathology. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17582596.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


3. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J: Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer; 2006 Aug 21;95(4):450-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
  • A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(-2) over 30 min every 21 days.
  • [MeSH-minor] Adenocarcinoma. Adult. Aged. Aged, 80 and over. Antineoplastic Agents. Female. Humans. Isoindoles. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1901-11 [11448903.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):653-8 [10995874.001]
  • [Cites] Int J Colorectal Dis. 2002 Jan;17(1):46-9 [12018454.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:13-22 [12401661.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):815-9 [12610179.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6004-7 [14522928.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):894-902 [14982966.001]
  • [Cites] Methods Mol Biol. 2004;281:91-103 [15220523.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Clin Chem. 1993 Feb;39(2):263-71 [8432015.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5487-95 [16061865.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6957-65 [16145066.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):203-7 [16333305.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):189-95 [10965817.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • (PMID = 16880795.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid; 0 / Antineoplastic Agents; 0 / Glutarates; 0 / Isoindoles; 0 / Quinazolines
  • [Other-IDs] NLM/ PMC2360664
  •  go-up   go-down


Advertisement
4. Tanigawa N, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, Kitajima M, Society for the Study of Postoperative Morbidity after Gastrectomy: Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. World J Surg; 2010 Jul;34(7):1540-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey.
  • BACKGROUND: Carcinoma of the gastric remnant after partial gastrectomy for benign disease or cancer is unusual but an important cancer model.
  • The Japanese Society for the Study of Postoperative Morbidity after Gastrectomy (JSSPMG) performed a nationwide questionnaire survey to understand the current state of gastric stump carcinoma in Japan.
  • METHODS: In the questionnaire survey of November 2008, gastric stump carcinoma was defined as an adenocarcinoma of the stomach occurring 10 years or more after Billroth I or Billroth II gastrectomy for benign condition or cancer disease.
  • The survey was conducted at the request of reports on five or more patients with gastric stump carcinoma for each institution.
  • A total of 887 patients were composed of 368 patients who received Billroth I distal gastrectomy and 519 who received Billroth II.
  • The Billroth II group has a significantly higher number of original benign lesions than the Billroth I group (P < 0.001).
  • (2) Patients with Billroth II gastrectomy had stump carcinomas most frequently in the anastomotic area, but not in the non-stump area as in Billroth I gastrectomy;.
  • (3) Tumor histology of 72.4% of 304 stump carcinomas at an early stage was intestinal type adenocarcinoma, i.e., well or moderately differentiated adenocarcinoma, whereas it decreased to 42.2% at the locally advanced stage of 521 stump carcinomas (P = 0.0015), suggesting that stump carcinoma mostly may develop from intestinal type and change to diffuse type during the evolution to advanced stage cancers.
  • CONCLUSIONS: This large series of surveys suggest that there are two distinct biological plausibilities in the development of gastric stump carcinoma:.
  • (1) it develops in a shorter time interval of 10 years or less since the original gastrectomy, may come from a higher risk of gastric mucosa after gastrectomy for cancer diseases that highly predisposes to cancer, and (2) it develops during a longer time interval of 20 years or more, may come from gastrectomy-relating mechanisms after gastrectomy for original benign diseases.
  • [MeSH-major] Adenocarcinoma / epidemiology. Gastric Stump. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1971 Apr;102(4):260-5 [4928618.001]
  • [Cites] Cancer. 1972 Jan;29(1):205-9 [5007382.001]
  • [Cites] Am J Surg. 1976 Jul;132(1):26-31 [952334.001]
  • [Cites] Lancet. 1976 Nov 13;2(7994):1037-9 [62896.001]
  • [Cites] Lancet. 1980 Apr 5;1(8171):727-9 [6103154.001]
  • [Cites] World J Surg. 1981 Jul;5(4):595-605 [7324494.001]
  • [Cites] N Engl J Med. 1982 Aug 26;307(9):519-22 [7099223.001]
  • [Cites] Br J Surg. 1983 Jun;70(6):322-5 [6860906.001]
  • [Cites] Br J Surg. 1983 Sep;70(9):552-4 [6616162.001]
  • [Cites] N Engl J Med. 1983 Nov 17;309(20):1210-3 [6633569.001]
  • [Cites] Cancer Res. 1984 May;44(5):2208-12 [6713408.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1431-5 [6587160.001]
  • [Cites] Clin Gastroenterol. 1984 May;13(2):569-600 [6378447.001]
  • [Cites] J Clin Pathol. 1984 Jul;37(7):748-54 [6747012.001]
  • [Cites] Lancet. 1986 Apr 26;1(8487):929-31 [2871238.001]
  • [Cites] Lancet. 1986 Aug 30;2(8505):502-5 [2875248.001]
  • [Cites] Jpn J Cancer Res. 1987 Apr;78(4):337-48 [3108214.001]
  • [Cites] N Engl J Med. 1988 Jul 28;319(4):195-200 [3393171.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):365-7 [3417364.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6486-9 [2145061.001]
  • [Cites] Langenbecks Arch Chir. 1991;376(1):16-22 [2034000.001]
  • [Cites] Gut. 1991 Jul;32(7):740-4 [1855679.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Carcinogenesis. 1992 Dec;13(12):2313-6 [1473239.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 18;85(16):1303-10 [8340942.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:3-11 [10209681.001]
  • [Cites] Ann Surg. 1956 Feb;143(2):173-9 [13292871.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2002;5(1):23-8 [12021856.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1:85-9 [15298611.001]
  • (PMID = 20182716.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2895900
  • [Investigator] Katai H; Takashima S; Kinoshita T; Yamamura Y; Kunisaki T; Tajiri T; Takenaka A; Otsuji E; Fuji Y; Tsurumaru M; Ogawa K; Saito H; Ota T; Nagai H; Yamazaki Y; Kaminishi M; Takiyama W; Sakuramoto S; Sasaki M; Tanigawa N; Hirakawa K; Fujiya T; Fujii H; Iwasaka N; Ooi E; Matsubara Y; Matsushita T; Tatsumi M; Yamamoto Y; Arita T; Wakabayashi G; Takiguchi N; Kitamura M; Nagata N; Watanabe S; Kimura W; Bandai Y; Kasai S; Hishiyama T; Yamada T; Kitano S; Monden M; Takabatake T; Yoshikawa T; Maehara Y; Oshita H; Nashimoto A; Ishida H; Sasaki I; Ishikawa H; Tani T; Kurita H; Kumagai K; Kusano M; Furukawa H; Konishi F; Kondo Y; Nakada K; Yamamoto M; Iwasaki Y; Inada T; Arai K; Sunagawa M; Shimizu T; Tamiya Y; Tokunaga A; Takayama T; Ishida Y; Ninomiya M; Goto M; Uyama I; Naito H; Mochizuki H; Miyata N; Naito H; Oka M; Tsuji T; Miyashiro I; Aoki T; Kanematsu T; Morita T; Tanaka K; Monden T; Yamasaki Y; Takahashi M; Fujii Y; Shiozaki H; Sugiyama Y
  •  go-up   go-down


5. Chen JS, Rau KM, Chen YY, Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su YC, Kao RH: A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. Cancer Chemother Pharmacol; 2009 Apr;63(5):819-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
  • PURPOSE: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer.
  • METHODS: Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2.
  • CONCLUSIONS: Biweekly, oxaliplatin combining oral tegafur-uracil/leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663448.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
  •  go-up   go-down


6. Sakai A, Tsuji Y, Kikuchi O, Jinno A, Tanabe W, Terashima Y, Maeda Y, Doi A, Hata T, Yamamoto N, Aoyama I, Arai O, Kiyosuke Y, Katayama S, Hirao K, Miyoshi M, Mouri H, Matsueda K, Yamamoto H: [Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence after the 23 years of gastric cancer operation by autopsy findings]. Gan To Kagaku Ryoho; 2008 Mar;35(3):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence after the 23 years of gastric cancer operation by autopsy findings].
  • A 70-year-old woman who underwent proximal gastrectomy for gastric cancer (poorly-differentiated adenocarcinoma) of Stage IIIB at age 46 visited our hospital April 2004 because of exacerbated pain by movement in the buttocks since November 2003.
  • Pancreas cancer or gallbladder cancer was suspected by CT, and a high tumor marker score (CA19-9 18,625 U/mL, DUPAN-II 15,000 U/ mL elevations were acknowledged).
  • The autopsical result revealed recurrence of gastric cancer 23 years post-operatively.


7. Park DJ, Kong SH, Lee HJ, Kim WH, Yang HK, Lee KU, Choe KJ: Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery; 2007 Jun;141(6):757-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN).
  • BACKGROUND: We investigated prognostic differences according to nodal status in patients with pT2a and pT2b stage gastric cancers.
  • METHODS: The clinicopathologic outcomes of 1118 patients who underwent curative resection and had 15 or more lymph nodes evaluated for pT2 stage gastric cancers between 1986 and 1996 were reviewed retrospectively.
  • Of the study group, 442 (39.5%) patients had pT2a stage gastric cancers and 676 (60.5%) had pT2b stage gastric cancers.
  • The prognosis of patients with pT2a gastric cancers was significantly better than that of patients with pT2b cancers on any pN stage (P < .001).
  • Multivariate analysis identified age, pT, and pN stages as independent prognostic factors for patients with pT2 gastric cancers.
  • Patients with pT2aN0 (stage IB) cancers showed the best survival.
  • Patents with pT2aN1 (stage II) and pT2bN0 (stage IB) cancers had similar survival rates, as did patients with pT2aN2 (stage IIIA) and pT2bN1 (stage II) cancers.
  • CONCLUSIONS: The subclassification of pT2 gastric cancers into pT2a or pT2b is necessary to demonstrate their different prognoses.
  • We propose that the current stage grouping should be modified to better represent the prognosis for patients with stage pT2 gastric cancers.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lymph Nodes / pathology. Stomach Neoplasms / classification. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560252.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Kostić Z, Cuk V, Bokun R, Ignjatović D, Usaj-Knezević S, Ignjatović M: [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Apr;63(4):349-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma].
  • BACKGROUND/AIM: Peritoneal metastasis is a leading cause of therapeutic failure after an operative treatment of patients with gastric adenocarcinoma.
  • The aim of this study was to determine the frequency of the presence of free cancer cells in the peritoneal cavity in the patients surgically treated for gastric adenocarcinoma, and its relation to certain clinical, operative and pathohistological paramethers.
  • Immediately after the laparotomy, 200 ml physiologic saline, heated to 37 degrees C, was introduced into the abdominal cavity, mannualy dispersed and collected from the region around the gastric tumor and the pouch of Douglas.
  • The frequency of positive cytological findings was compared to the location and the diameter of the cancer, pathohistological type of carcinoma, pathohistological stage of the disease, lymph node and the liver and/or peritoneal metastases and the type of surgical procedure.
  • A statistically highly significant difference (p < or = 0.001) in the frequency of positive cytological finding was found between the groups of patients with and without cancer invasion of serosa, with cancer diameters > 5 cm and < or = 5 cm, in the stage of disease I, II and III, IV, with macroscopically present and without metastases, with re section and D2 lymphadenectomy and palliative procedure.
  • The results of the univariate analysis showed that the cancer diameter > 5 cm, tumor invasion of serosa, pathohistological stage of the disease III and IV and macroscopically visible metastases were the most important risk factors for the free cancer cells detection.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Neoplastic Cells, Circulating. Peritoneal Cavity / cytology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Apr;63(4):347-8 [16683400.001]
  • (PMID = 16683401.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


9. Koufuji K, Shirouzu K, Aoyagi K, Yano S, Miyagi M, Imaizumi T, Takeda J: Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction. Kurume Med J; 2005;52(3):73-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction.
  • To clarify the optimal operative procedure for gastric adenocarcinoma involving the esophago-gastric junction (EGJ), we investigated 49 cases with an upper gastric cancer invading the esophagus who underwent surgical treatment in our department during the period from 1991 to 2000.
  • According to Siewert's classification, there were 21 cases with a type II tumor, and 28 cases with a type III tumor.
  • Proximal gastrectomy was performed in 6 cases at the early stage and in 10 cases at the advanced stage with distant metastasis (M1).
  • Total gastrectomy was done in 33 cases at the advanced stage, and 3 of these 33 cases had metastasis to the parapyloric lymph nodes.
  • Tumors were stage I in 8 cases, II in 5 cases, III in 13 cases and IV in 23 cases, and the curability was categorized as A in 8 cases, B in 20 and C in 21.
  • The overall 5-year-survival rate was 25%, and the rates according to cancer stage were 86% for stage I, 40% for stage II , 21% for stage III and 0% for stage IV.
  • The 5-year survival rates of cases at stage II and III were 33% for cases using the left thoraco-abdominal approach and 28% for cases with the abdominal approach.
  • Based on these results, we recommend distal esophagectomy with total gastrectomy, and occasional combined resection of the spleen and the diaphragm through a left thoraco-abdominal approach for advanced gastric adenocarcinoma involving the EGJ.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422172.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA: Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol; 2005 May 1;23(13):3094-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years.
  • PURPOSE: To determine the clinicopathologic behavior of gastric adenocarcinoma in Hispanics by comparing Hispanic and non-Hispanic patients treated at a single cancer center.
  • PATIENTS AND METHODS: Medical records of patients with invasive gastric cancer treated from 1985 to 1999 were reviewed.
  • Hispanics were less likely to have proximal gastric cancers compared with whites (38.9% v 59.5%, respectively; P < .005).
  • In Cox analyses, Asian race, earlier stage, papillary/tubular histology, distal location, and younger age were favorable predictors of survival.
  • CONCLUSION: Hispanic ethnicity does not impact survival in gastric adenocarcinoma.
  • However, histology, metastasis pattern, tumor localization, and other clinical parameters differ sufficiently to warrant further investigation into the epidemiology, pathogenesis, and molecular biology of gastric cancer in this population.
  • [MeSH-major] Adenocarcinoma / pathology. Hispanic Americans. Neoplasm Metastasis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860869.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK: Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. Eur J Surg Oncol; 2007 Sep;33(7):843-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
  • AIM: This study aimed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), doxorubicin and mitomycin-C (FAM) adjuvant chemotherapy in patients who had undergone curative resection of gastric carcinoma.
  • METHODS: From Nov 1999 to Jan 2002, 291 consecutive patients with stage IB-IIIB gastric adenocarcinoma were given FAM adjuvant chemotherapy.
  • The 5-year overall survival (OS) rates were 85.9% for stage IB, 72.1% for stage II, 58.0% for stage IIIA, and 48.2% for stage IIIB (p=0.002).
  • The 5-year relapse-free survival (RFS) rates were 85.2% for stage IB, 71.2% for stage II, 53.3% for stage IIIA, and 39.2% for stage IIIB (p<0.001).
  • CONCLUSIONS: Adjuvant chemotherapy with FAM for 6 months for gastric carcinoma indicated comparable RFS and OS with an acceptable toxicity profile.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy / methods. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207959.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


12. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The section on breast cancer emphasizes that, although usually a manifestation of late stage disease and often not bulky in the ovaries, metastatic breast cancer may form large masses which can represent the clinical presentation.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


13. Carrato A, Gallego-Plazas J, Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol; 2005 Dec;32(6 Suppl 9):S105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy of resected gastric cancer is necessary.
  • The currently reported 5-year survival rates for patients with resected stage II, IIIA, IIIB, and IV gastric cancer are 34%, 20%, 8%, and 7%, respectively.
  • Other agents in combination with perioperative radiotherapy and surgery are being investigated to treat patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399445.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia]. Chin J Cancer; 2010 Jan;29(1):94-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia].
  • BACKGROUND AND OBJECTIVE: The incidence of adenocarcinoma of the cardia has recently increased.
  • This study compared the clinicopathology and prognosis of patients with gastric cardia adenocarcinoma in different periods between 1984 and 2003.
  • METHODS: A total of 589 patients with pathologically confirmed gastric cardia adenocarcinoma hospitalized in Sun Yat-sen University Cancer Center between 1984 and 2003 were divided into 5-year groups.
  • The rates of patients with the stage-I and -II disease changed insignificantly, while patients with stage-III disease increased, and patients with stage-I disease decreased.
  • CONCLUSIONS: During the past 20 years, associated with the upward-trending incidence of gastric cardia adenocarcinoma, the admission rate at our hospital of patients with the tumor increased.
  • The proportion of patients with late-stage disease decreased and prognosis has improved.
  • [MeSH-major] Adenocarcinoma. Cardia / pathology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038318.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, Walther B: Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg; 2008 Jun;32(6):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.
  • BACKGROUND: Adenocarcinoma at the gastroesophageal junction may be regarded as of esophageal or of gastric origin, and tumor removal may follow the principles of esophagectomy or extended gastrectomy.
  • METHODS: Baseline patient and tumor characteristics were collected, and tumors were categorized according to Siewert's classification (I, II, or III) of gastroesophageal junction tumors.
  • Ninety-six patients with type I (n = 67), II (n = 26), and III (n = 3) tumors underwent esophagectomy and gastric tube reconstruction, and 37 patients with type I (n = 5), II (n = 26), and III (n = 6) tumors underwent extended gastrectomy and long Roux-en-Y reconstructions.
  • RESULTS: After adjusting for the independently significant impact factors-tumor stage, tumor dissection (R0-R2), and length of tumor free resection margins-we did not find any specific survival benefit associated with either of the two evaluated surgical approaches for tumor resection and reconstruction.
  • CONCLUSIONS: Provided that adequate tumor dissection is performed, patients with adenocarcinoma at the gastroesophageal junction can be resected and reconstructed using the principles for esophagectomy or extended gastrectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery


16. Căinap C, Părău A, Muntean A, Hodorog A, Vlad L: [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy].
  • [Transliterated title] Chimioterapia de generaţie nouă in cancerul gastric operat--o alternativă la chimioterapia clasică.
  • Gastric cancer remains one of the most difficult tumour type despite his relative reduction of his global incidence, it remains on of the most deadly cancer.
  • The latest advances in therapy of the gastric cancer ameliorate the results in terms of survival.
  • In our prospective, non-randomized study, we enrolled 40 patients with gastric adenocarcinoma stage IB to IV (M0) who were surgically treated, treated with chemoradioterapy, but with chemotherapy modified by ECX (epirubicine, cisplatine, xeloda) which is now considered standard in metastatic setting.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405677.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR: Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg; 2006 Jan;243(1):74-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe.
  • -derived nomogram for individual prediction of disease-specific gastric cancer survival at a European institution.
  • For gastric cancer, Kattan et al, at Memorial Sloan-Kettering Cancer Center, New York, NY, developed a nomogram, allowing to predict individual patient risk of tumor-related death after R0 resection from basic patient-related variables.
  • The accuracy of the nomogram when applied to patients after having undergone R0 gastric cancer resection at a European high-volume center was investigated.
  • METHODS: Clinical data from patients who underwent R0 gastric cancer resection at Klinikum rechts der Isar, Technical University of Munich, Germany and fitted the respective derivation criteria were used for external validation (n = 862).
  • RESULTS: The bootstrap-corrected concordance index was 0.77 and was superior when compared with the predictive ability of International Union Against Cancer tumor stage (P < 0.008).
  • Nomogram predictions showed the trend to underestimate survival in stage II/III disease of the MRI patients.
  • [MeSH-major] Adenocarcinoma / mortality. Gastrectomy / mortality. Nomograms. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):233-7 [10782897.001]
  • [Cites] Ann Surg Oncol. 2000 Jun;7(5):346-51 [10864341.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):878-80 [11286464.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):832-8 [11351303.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):771-4 [12374660.001]
  • [Cites] J Pathol. 2003 May;200(1):39-46 [12692839.001]
  • [Cites] Langenbecks Arch Surg. 2003 Sep;388(4):245-9 [12861416.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3647-50 [14512396.001]
  • [Cites] Surgery. 2003 Oct;134(4):720-7; discussion 727-9 [14605635.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):240-4 [15019915.001]
  • [Cites] Jpn J Surg. 1981 Mar;11(2):127-39 [7300058.001]
  • [Cites] JAMA. 1982 May 14;247(18):2543-6 [7069920.001]
  • [Cites] Surg Gynecol Obstet. 1986 Mar;162(3):229-34 [3952614.001]
  • [Cites] Chirurg. 1987 Jan;58(1):25-32 [3829805.001]
  • [Cites] Arch Surg. 1989 Mar;124(3):314-8 [2919965.001]
  • [Cites] World J Surg. 1989 Jan-Feb;13(1):118-23; discussion 123 [2471364.001]
  • [Cites] Hepatogastroenterology. 1989 Feb;36(1):7-12 [2744714.001]
  • [Cites] Arch Surg. 1989 Sep;124(9):1061-4 [2774908.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1034-8 [1670998.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):825-7 [1873712.001]
  • [Cites] Chirurg. 1992 Aug;63(8):656-61 [1395862.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3179-84 [7902202.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2900-7 [8187075.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1503-7 [7889482.001]
  • [Cites] Int J Cancer. 1995 Feb 20;64(1):32-6 [7665246.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):593-600 [7677173.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):617-21 [7559076.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1144-7 [8869330.001]
  • [Cites] Chirurg. 1996 Sep;67(9):877-88 [8991768.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):678-83; discussion 683-5 [9230808.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1641-5 [9427036.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1651-64 [9448610.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):611-9 [10027338.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1033-8 [10091785.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):214-9 [10440758.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 16371739.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1449962
  •  go-up   go-down


18. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, Vecchione L, Romano A, Martinelli E, Renda A, Ferraraccio F, Del Genio A, Ciardiello F, Galizia G: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg; 2010 Mar;145(3):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study.
  • BACKGROUND: Adjuvant chemoradiotherapy does not represent the standard of care in patients with resected high-risk gastric cancer; however, results from phase 2 and randomized trials suggest improvement in overall survival.
  • We assessed the feasibility and toxic effects of chemoradiotherapy as adjuvant treatment in locally advanced gastric cancer.
  • PATIENTS: Twenty-nine patients with T4N+ or any TN23 gastric cancer previously treated with potentially curative surgery were enrolled.
  • Long-term outcome was related to TNM stage, basal serum tumor marker level, and, particularly, lymph node ratio.
  • CONCLUSION: A multimodal approach with FOLFOX-4 and radiotherapy is feasible and effective for the treatment of patients with resected high-risk gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2010 Mar;145(3):239 [20329345.001]
  • (PMID = 20231623.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Evtushenko VA, Vusik MV, Karakeshisheva MB, Pleshko RI, Ermolaeva LA: [Characteristic of inflammatory infiltrate of gastric mucosa in patients with grade II-III gastric dysplasia and of stomach cancer]. Klin Med (Mosk); 2008;86(11):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristic of inflammatory infiltrate of gastric mucosa in patients with grade II-III gastric dysplasia and of stomach cancer].
  • The study included 85 inpatients and outpatients in whom composition of inflammatory infiltrate from gastric mucosa (GM) was determined at the Oncological Research Institute, Tomsk Research Centre of the Siberian Division, Russian Academy of Medical Sciences.
  • Group 1 comprised 21 patients with grade II-III GM epithelial dysplasia, group 2 - 24 patients having stomach cancer (histologically confirmed adenocarcinoma), group 3 - 19 patients with stage II-III mucinous gastric carcinoma, group 4 - 20 allegedly healthy subjects without signs of gastrointestinal pathology.
  • Mucinous gastric carcinoma was characterized by an increase of the number of neutrophils and macrophages.
  • Patients having adenocarcinoma of the stomach showed enhanced plasmocytic infiltration by plasmocytes with a low number of eosinophils and mast cells.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Neoplasm Staging. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177795.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


20. Han FH, Zhan WH, Li YM, He YL, Peng JS, Cai SR, Ma JP, Wang Z: [Analyses of surgical treatment and prognosis in gastric stump cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analyses of surgical treatment and prognosis in gastric stump cancer].
  • OBJECTIVE: To evaluate the efficacy of surgical treatment and the prognosis in gastric stump cancer patients.
  • METHODS: Between June 1994 and March 2004, 692 patients underwent radical operation for gastric cancer in our department.
  • Among them, 22 cases were gastric stump cancer.
  • RESULTS: Gastric stump cancer accounted for 3.2 % of all the gastric cancer cases in the same period.
  • There were 4 cases of stage I, 2 cases of stage II, 6 cases of stage III and 10 cases of stage IIII respectively.
  • Radical gastric stump cancer excisions were finished with abdominal incision in 18 cases and with thoraco-abdominal incision in 4 cases.
  • Average survival time was(80.2+/-17.2) months in stage I( and II( gastric remnant cancer; average survival time was(31.2+/-9.2) months in stage III( gastric remnant cancer, average survival time was (23.6+/-6.1) months in stage IIII( gastric remnant cancer, which were significantly different(all P<0.05).
  • Between palliative operation group and standard radical excision, extended radical excision groups, well-moderate differentiated and poor differentiated adenocarcinoma groups, lymph node metastasis positive and negative groups, the differences were all significant.
  • CONCLUSIONS: Total gastrectomy and D(2) lymph node dissection are imperative for radical excision of gastric remnant cancer.
  • Tumor stage, procedure pattern, lymph node metastasis and tumor differentiation affect the prognosis of patients with gastric stump cancer.
  • [MeSH-major] Gastric Stump / pathology. Gastric Stump / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145499.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Oro S, Tatebe S, Tsujitani S, Ikeguchi M: Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg; 2006 Sep;192(3):296-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer.
  • BACKGROUND: In some cancers, such as breast and lung, tumor size is included in the classification of disease stage.
  • However, it's clinical significance remains elusive in gastric cancer.
  • METHODS: To investigate the prognostic significance of macroscopic tumor size, we reviewed 1473 gastric cancer patients who underwent curative gastrectomy.
  • The survival rates of patient with stages II-, IIIa-, and IIIb-LSG disease were almost the same as those with stages IIIa-, IIIb-, and IV-SSG disease, respectively.
  • COMMENTS: Tumor size serves as a simple predictor of survival in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Tumor Burden

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920421.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues (0, 30%, 20% and 0, respectively, P<0.01).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05).
  • The expression of Topo-II was associated with increasing differentiated degree (33.3%, 69.7% and 80.7%, P<0.01).
  • No significant differences with Topo-II expression was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 72.4%, P>0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. without metastasis, 70.0% vs. 41.4%, P<0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0%, 26.1%, 7.24%, 5.8%, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


23. Früh M, Ruhstaller T, Neuweiler J, Cerny T: Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie; 2005 Jan;28(1):38-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation.
  • BACKGROUND: Skin metastases from gastric cancer are rare and generally occur at a very late stage in the course of the disease.
  • CASE REPORT: A 60-year-old patient with localized adenocarcinoma of the cardia (stage II) was primarily treated with extended total gastrectomy with transhiatal resection of the distal esophagus.
  • CONCLUSION: We report a long-term disease-free survival of a patient with isolated cutaneous metastases of a gastric cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Skin Neoplasms / secondary. Skin Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604627.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Griniatsos J, Gakiopoulou H, Yiannakopoulou E, Dimitriou N, Douridas G, Nonni A, Liakakos T, Felekouras E: Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer. World J Gastroenterol; 2009 Nov 28;15(44):5568-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer.
  • AIM: To evaluate routine modified D2 lymphadenectomy in gastric cancer, based on immunohistochemically detected skip micrometastases in level II lymph nodes.
  • METHODS: Among 95 gastric cancer patients who were routinely submitted to curative modified D2 lymphadenectomy, from January 2004 to December 2008, 32 were classified as pN0.
  • The level II lymph nodes of the remaining 28 patients were studied immunohistochemically for micrometastases detection and constitute the material of the present study.
  • RESULTS: Skip micrometastases in the level II lymph nodes were detected in 14% (4 out of 28) of the patients.
  • The incidence was further increased to 17% (4 out of 24) in the subgroup of T1-2 gastric cancer patients.
  • Thus, the disease was upstaged from stage IA to IB in one patient and from stage IB to II in three patients.
  • CONCLUSION: In gastric cancer, true R0 resection may not be achieved without modified D2 lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Lymph Node Excision / methods. Lymphatic Metastasis / diagnosis. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):833-54, ix [11641094.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):609-13 [19137375.001]
  • [Cites] Gastric Cancer. 2002;5(1):1-5 [12021853.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2867-73 [12115374.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):601-4 [12680154.001]
  • [Cites] World J Surg. 2003 May;27(5):558-61 [12715223.001]
  • [Cites] Melanoma Res. 2003 Jun;13(3):313-24 [12777989.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):303-8 [15028313.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(4):CD001964 [15495024.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):241-5 [1371897.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2289-94 [8708719.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1393-8 [9338462.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):225-33 [15620948.001]
  • [Cites] Gastric Cancer. 2005;8(2):64-70 [15864711.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):153-65 [15895448.001]
  • [Cites] ANZ J Surg. 2005 Aug;75(8):645-9 [16076325.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1135-44 [16096401.001]
  • [Cites] World J Gastroenterol. 2005 Oct 14;11(38):5920-5 [16273600.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):341-7 [16495698.001]
  • [Cites] Gastric Cancer. 2006;9(3):197-202 [16952038.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2143-51 [17001662.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):81-4 [17419236.001]
  • [Cites] Gastric Cancer. 2007;10(2):87-91 [17577617.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2028-35 [17453300.001]
  • [Cites] J Surg Oncol. 2007 Jul 1;96(1):14-8 [17582596.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jun;37(6):429-33 [17656480.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2432-4 [17520315.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):125-30 [18095267.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):550-4 [17786527.001]
  • [Cites] Ann Surg Oncol. 2008 Mar;15(3):770-6 [18157577.001]
  • [Cites] Surg Oncol. 2008 Sep;17(3):203-10 [18539025.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1574-80 [19001602.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):603-8 [19127361.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):495-9 [11696619.001]
  • (PMID = 19938196.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2785060
  •  go-up   go-down


25. Chen C, Chen LQ, Chen LD, Yang GL, Li Y: Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. Hepatogastroenterology; 2008 May-Jun;55(84):991-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases.
  • This work is to evaluate this C12 system in the diagnosis of gastric cancer.
  • METHODOLOGY: Sera from 100 gastric carcinoma patients were screened for 12 tumor markers including carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 19-9, carbohydrate antigen 242, cancer antigen 15-3, cancer antigen 125, prostate specific antigen, free-PSA, neuron-specific enolase, human chorionic gonagotropin-beta, human growth hormone, and ferritin, using the C12 biochip system.
  • RESULTS: The overall diagnostic rate of C12 biochip system was 37%, and 7.8%, 29.4%, 35.5% and 50%, respectively, for stages I, II, III and IV patients.
  • The differences in diagnostic rates between stage I (7.8%) and stage IV (50%) reached statistical significance (chi-square test, Chi2=7.20, p<0.01).
  • CONCLUSIONS: The C12 biochip system has some value in the diagnosis of advanced stage gastric cancer, but less sensitive in early gastric cancer.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Young Adult


26. Kolodziejczyk P, Kulig J, Popiela T, Sierzega M, Jedrys J, Czupryna A, Kubisz A, Szczepanik A, Klek S, Polish Gastric Cancer Study Group: Outcome of gastric cancer surgery in elderly patients. Hepatogastroenterology; 2005 Nov-Dec;52(66):1911-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of gastric cancer surgery in elderly patients.
  • BACKGROUND/AIMS: The aim of the study was to review cases of gastric cancers in elderly adults (70 years of age and older), and compare demographic, clinical, pathologic features and outcomes of surgical treatment with younger patients (below 70 years of age).
  • METHODOLOGY: The analysis included 3431 patients treated for gastric cancer between 1977 and 1998 at eight university surgical centers cooperating for the Polish Gastric Cancer Study Group (PGCSG).
  • Patients were analyzed retrospectively according to data obtained from standardized forms and divided into two groups: group I--patients 70 years of age and over, group II--younger patients.
  • The overall 5-year survival was 24% and 35% for group I and II, respectively (p<0.05), and increased to 35% and 53% after radical resections, respectively.
  • However, there were no statistically significant differences in stage-specific survival between both groups.
  • CONCLUSIONS: Surgical resection is the method of choice in the treatment of gastric cancer.
  • Age of the patients is not a contraindication to surgical treatment of gastric cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Postoperative Complications / epidemiology. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334805.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


27. Blackshaw G, Lewis WG, Hopper AN, Morgan MA, Al-Khyatt W, Edwards P, Roberts SA: Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer. Clin Radiol; 2008 Oct;63(10):1092-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer.
  • AIMS: To assess the strength of agreement between the perceived preoperative stage of Siewert II (oesophagogastric junction) and Siewert III (proximal gastric tumours) as determined by computed tomography (CT) and endoscopic ultrasound (EUS), both alone and in combination, with histopathological stage.
  • METHODS: Forty-four patients with Siewert II (n=18) and III (n=26) adenocarcinomas of the oesophagogastric junction underwent preoperative CT at their local hospitals followed by specialist EUS, and the strengths of the agreement between the radiological stages and the histopathological stages were determined by the weighted Kappa statistic (Kw).
  • RESULTS: Kw for Siewert II T and N stages was 0.491 (p=0.016) and 0.4 (p=0.087) for CT compared with 0.852 (p=0.0001) and 1 (p=0.0001) for EUS.
  • CONCLUSION: Siewert II tumour T and N stages were more accurately predicted by EUS than CT, but Siewert III tumour T and N stages were more difficult to assess, arguably because of anatomical constraints at the oesophagogastric junction.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774355.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Solerio D, Camandona M, Gasparri G, Casalegno PA, Raggio E, Dei Poli M: [The choice of surgical therapy in adenocarcinoma of the cardia]. Minerva Chir; 2005 Feb;60(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The choice of surgical therapy in adenocarcinoma of the cardia].
  • [Transliterated title] La scelta della terapia chirurgica nell'adenocarcinoma del cardias.
  • AIM: From 1996 the adenocarcinoma of the esophago-gastric junction (AEG) is divided into 3 types according to Siewert's classification.
  • For AEG type I and III the surgical treatment is codified, while for type II is still controversial.
  • The aim of our study is to understand what is the better surgical treatment for AEG type II.
  • METHODS: From 1990 to 2002 we have performed 111 resections for adenocarcinoma of the cardia: 25 for AEG type I (all esophago-gastric resection), 39 for type II (22 esophago-gastric resection, 17 extended total gastrectomy with esophageal resection) and 47 for type III (8 esophago-gastric resection, 39 extended total gastrectomy with esophageal resection).
  • For AEG type II any significant difference in survival is associated with surgical strategy, also in early stage (p>0.01).
  • CONCLUSIONS: According to the results of our study and those of the other authors, who have showed that a 10 cm distance of the neoplasm by the gastric side and the esophageal one could assure oncologic radicality and also that metastatic lymph nodes below pylorus and near greater curvature are uncommon, we can consider esophago-gastric resection for AEG II a speedy, safe and oncologically correct surgical treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902049.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC: TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res; 2007 May 15;139(2):182-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival.
  • BACKGROUND: This study evaluates the expression of transforming growth factors TGFbeta1, TGFbeta2 and TGFbeta3 in cases of gastric carcinoma and their possible correlation with classic prognostic markers and patient survival.
  • MATERIALS AND METHODS: The study included 110 gastrectomy specimens obtained from equal number of patients with gastric cancer.
  • According to the TNM classification, 7 tumors were identified as being stage I, 33 stage II, 52 stage III, and 18 stage IV, whereas 92 tumors were low-grade and 18 high-grade malignancies.
  • Normal gastric mucosal epithelial cells expressed TGFbeta2 and TGFbeta3, but not TGFbeta1.
  • TGFbeta2 presence was higher in advanced stage tumors (P = 0.008) and was correlated with worse prognosis (P < 0.05).
  • CONCLUSIONS: Gastric carcinoma is related to differential expression of TGFbeta1, TGFbeta2, and TGFbeta3.
  • [MeSH-major] Adenocarcinoma / metabolism. Stomach Neoplasms / metabolism. Transforming Growth Factor beta1 / metabolism. Transforming Growth Factor beta2 / metabolism. Transforming Growth Factor beta3 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270215.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 0 / Transforming Growth Factor beta2; 0 / Transforming Growth Factor beta3
  •  go-up   go-down


30. Wals A, Contreras J, Macías J, Fortes I, Rivas D, González P, Herruzo I: Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. Clin Transl Oncol; 2006 Apr;8(4):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
  • OBJECTIVE: To calculate the Normal Tissue Complication Probabilities (NTCP) for the liver, right kidney, left kidney and spinal cord, as well as the global Uncomplicated Tumour Control Probability (UTCP) in gastric cancer patients who underwent a treatment with radiotherapy after radical surgery in our environment.
  • MATERIAL AND METHOD: In April 2000, a postoperative chemotherapy (QT-RT) protocol started in the province of Malaga for Gastric Adenocarcinomas with postsurgical stage II or higher (pT3-4 and/or pN+).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Algorithms. Kidney / radiation effects. Liver / radiation effects. Radiation Injuries / diagnosis. Radiotherapy, Adjuvant / adverse effects. Spinal Cord / radiation effects. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46 [2032884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):283-93 [11872272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30 [2722599.001]
  • [Cites] Radiat Res Suppl. 1985;8:S13-9 [3867079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):439-47 [10760441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35 [2032883.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):589-98 [10701738.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):983-93 [10705021.001]
  • (PMID = 16648103.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Jang YJ, Park MS, Park SS, Kim JH, An H, Park SH, Kim SJ, Kim CS, Mok YJ: Surgeon subspecialty as a factor in improving long-term outcomes for gastric cancer: Twenty years of experience in Korea. Arch Surg; 2010 Nov;145(11):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon subspecialty as a factor in improving long-term outcomes for gastric cancer: Twenty years of experience in Korea.
  • BACKGROUND: The results of gastric cancer treatment have improved during the past 2 decades.
  • This study analyzed data accumulated during the past 20 years regarding the impact of surgical subspecialty on gastric cancer prognosis.
  • PATIENTS: A total of 2797 patients admitted between 1984 and 2003 with surgically treated, pathologically confirmed, primary gastric adenocarcinoma.
  • A Cox proportional hazards regression model showed that age, sex, tumor location, type of resection, stage, and the interaction between period of study and surgical subspecialty were independent prognostic factors.
  • CONCLUSIONS: This large, long-term cohort study demonstrates that the management of gastric cancer has been largely successful, with favorable trends in prognostic factors.
  • Successful outcomes are realized more often by gastric surgical specialists.
  • Efforts must be made to improve the treatment of patients with stage II gastric cancer because the improvements in long-term results have plateaued.
  • [MeSH-major] Adenocarcinoma / surgery. Clinical Competence. Gastrectomy / methods. Specialties, Surgical. Stomach Neoplasms / surgery. Workload

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2010 Nov;145(11):1096-7 [21121098.001]
  • (PMID = 21079098.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Fareed KR, Ilyas M, Kaye PV, Soomro IN, Lobo DN, Parsons SL, Madhusudan S: Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology; 2009 Oct;55(4):399-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Neoadjuvant chemotherapy followed by surgery is the standard of care for patients with gastro-oesophageal adenocarcinoma.
  • The aims were to validate the utility of the tumour regression grade (TRG) in patients who have received chemotherapy and to investigate if (i) TRG correlates with tumour downstaging and (ii) TRG could provide a comparative platform for future predictive biomarker investigations.
  • In the neoadjuvant chemotherapy (CS) group (n = 84), 46.7% of gastric/gastro-oesophageal junction adenocarcinomas, and 45.5% of lower third oesophageal adenocarcinomas had TRG 1, 2 or 3 compared with 13.7% in the primary surgery group (n = 124) (P < 0.001 and P = 0.006, respectively).
  • In the CS group, responders (TRG 1, 2 or 3) showed significant tumour downstaging [early ypT-stage disease (P = 0.002)].
  • In gastric cancers specifically, additional associations were seen with negative nodal disease (P = 0.044) and absence of vascular invasion (P = 0.027).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / surgery. Neoadjuvant Therapy / methods. Platinum / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817890.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 49DFR088MY / Platinum; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  •  go-up   go-down


33. Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY, Zhao ZS, Tao HQ: Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken); 2010 Nov;293(11):1855-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test.
  • The aim of this study was to explore the clinical significance of neutrophil gelatinase-associated lipocalin (NGAL) in the development and prognosis of gastric cancer.
  • NGAL in blood samples from 63 healthy donors and 60 gastric cancer patients were also determined by enzyme-linked immunosorbent assay.
  • Rate of NGAL expression was correlated with the size of tumor (69.3% in >4 cm tumors vs. 46.1% in ≤4 cm tumors), Lauren's classification (84.3% in diffuse type vs. 28.2% in intestinal type), lymph node metastasis (75.6% vs. 16.4% with no metastasis), vascular invasion (74.9% vs. 26.8% with no invasion), distant metastasis (94.3% vs. 50.3% with no distant metastasis), and TNM stage (81.8% in TNM III+IV vs. 20.5% in TNM I+II).
  • NGAL expression can be used as an independent prognostic factor in gastric cancer as indicated by multivariate analysis.
  • Positivity for serum NGAL was higher than that for carbohydrate antigen determinant, CA19-9 (38.1% vs. 12.5%) in TNM I, and higher than that for carcinoembryonic antigen, CEA (58.3% vs. 8.3%) and CA19-9 (58.3% vs. 8.3%) in TNM II.
  • In conclusion, serum NGAL has great potential to be used as an ancillary test for diagnosis of gastric cancer.
  • Increased expression of NGAL in tumors suggests gastric cancer is likely to be at an advanced stage with invasion and metastasis, and also poor prognosis.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Lipocalins / metabolism. Proto-Oncogene Proteins / metabolism. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730863.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


34. Kassam Z, Lockwood G, O'brien C, Brierley J, Swallow C, Oza A, Siu L, Knox JJ, Wong R, Cummings B, Kim J, Moore M, Ringash J: Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):713-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
  • BACKGROUND: The Intergroup 0116 study showed a survival benefit with adjuvant chemoradiotherapy (CRT) for resected gastric cancer.
  • METHODS AND MATERIALS: Eighty-two patients with resected gastric or gastroesophageal junction (GEJ) adenocarcinoma, Stage IB to IV (M0), were treated with 45 Gy in 25 fractions using a 5-field conformal technique.
  • Chemotherapy was in accordance with the Intergroup 0116 study, or infusional 5-fluorouracil and cisplatin in a phase I/II trial.
  • CONCLUSION: Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Radiotherapy, Conformal. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626887.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Harada K, Noguchi T, Fujiwara S, Moriyama H, Kitano S, Kawahara K: [Complete response in an elderly patient with advanced gastric cancer treated with TS-1]. Gan To Kagaku Ryoho; 2007 Mar;34(3):427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response in an elderly patient with advanced gastric cancer treated with TS-1].
  • He was diagnosed with advanced gastric cancer, T2N1H0P0M0, stage II.
  • From now on, as society grays more and more, it is considered that elderly advanced gastric cancer patients with complications will increase.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353636.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


36. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol; 2005 Jun 1;90(3):139-46; discussion 146
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.
  • A topographic-anatomic subclassification of adenocarcinomas of the esophago-gastric junction (AEG) in distal esophageal adenocarcinoma (AEG Type I), true carcinoma of the cardia (AEG Type II), and subcardial gastric cancer (AEG Type III) was introduced in 1987 and is now increasingly accepted and used worldwide.
  • While underlying specialized intestinal metaplasia can be found in basically all patients with AEG Type I tumors, this is uncommon in Type II tumors and virtually absent in Type III tumors.
  • Stage distribution and overall long-term survival after surgical resection also shows marked differences between the AEG subtypes.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms / classification. Esophagogastric Junction. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15895452.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


37. Ichikura T, Chochi K, Sugasawa H, Mochizuki H: Proposal for a new definition of true cardia carcinoma. J Surg Oncol; 2007 Jun 1;95(7):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: It remains controversial whether cardia carcinoma should be categorized and treated as esophageal cancer or gastric cancer.
  • METHODS: Patients with Siewert type II carcinomas were divided into two subgroups: 25 patients with a tumor center within 1 cm of the esophagogastric junction (EGJ) (type IIA) and 22 patients with tumor center 1-2 cm aboral of the EGJ (type IIB).
  • RESULTS: The patients with type IIB carcinomas showed no different characteristics from those with type III or type IIIe- carcinomas, except for the stage of the disease.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Esophagogastric Junction. Stomach Neoplasms / classification. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17192914.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H: Plasma adiponectin and gastric cancer. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):466-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma adiponectin and gastric cancer.
  • BACKGROUND: Recently, increased body weight has been associated with an increased risk of cancers at multiple specific sites, including gastric cancer.
  • METHODS: Fasting plasma levels of adiponectin were determined in 75 patients with gastric cancer and 52 healthy controls using an ELISA.
  • In these patients, we analyzed the association between plasma adiponectin level and gastric cancer risk as well as various clinicopathologic characteristics.
  • RESULTS: Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 +/- 6.2 versus 13.3 +/- 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different.
  • In addition, adiponectin level was extremely low in patients with upper gastric cancers (upper, 5.5 +/- 4.1 ng/mL; middle, 9.7 +/- 6.4 ng/mL; lower, 10.7 +/- 4.1 ng/mL; P = 0.012).
  • Furthermore, adiponectin level tended to decrease as the tumor stage increased (stage I, 9.9 +/- 6.9 ng/mL; stage II, 8.7 +/- 5.5 ng/mL; stage III, 8.6 +/- 4.1 ng/mL; stage IV, 5.2 +/- 6.2 ng/mL; P = 0.34).
  • Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer.
  • CONCLUSIONS: Our results suggest that a low plasma adiponectin level is associated with an increased risk for gastric cancer and raise the possibility that adiponectin has a potential role in the progression of gastric cancer, especially in undifferentiated type cancers in the upper stomach.
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / etiology. Adiponectin. Body Mass Index. Carcinoma, Signet Ring Cell / blood. Carcinoma, Signet Ring Cell / etiology. Case-Control Studies. Cell Differentiation. Collagen / blood. Down-Regulation. Fasting. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701829.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG 21418; United States / NCI NIH HHS / CA / R01 CA 1018447; United States / NIDDK NIH HHS / DK / T32 DK 07790
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Intercellular Signaling Peptides and Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


39. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ: Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol; 2005 Feb 7;11(5):623-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.
  • AIM: To investigate the expression of mitogen-activated protein kinases (MAPKs) and its upstream protein kinase in human gastric cancer and to evaluate the relationship between protein levels and clinicopathological parameters.
  • METHODS: Western blot was used to measure the expression of extracellular signal-regulated kinase (ERK)-1, ERK-2, ERK-3, p38 and mitogen or ERK activated protein kinaseMEK-1 proteins in surgically resected gastric carcinoma, adjacent normal mucosa and metastatic lymph nodes from 42 patients.
  • RESULTS: Compared with normal tissues, the protein levels of ERK-1 (integral optical density value 159 526+/-65 760 vs 122 807+/-65 515, P = 0.001), ERK-2 (168 471+/-95 051 vs 120 469+/-72 874, P<0.001), ERK-3 (118 651+/-71 513 vs 70 934+/-68 058, P<0.001), P38 (104 776+/-51 650 vs 82 930+/-40 392, P = 0.048) and MEK-1 (116 486+/-45 725 vs 101 434+/-49 387, P = 0.027) were increased in gastric cancer tissues.
  • Overexpression of ERK-3 was correlated to TNM staging (average ratio of integral optic density (IOD)(tumor): IOD(normal) in TNM I, II, III, IV tumors was 1.43+/-0.34, 5.08+/-3.74, 4.99+/-1.08, 1.44+/-1.02, n = 42, P = 0.023) and serosa invasion (4.31+/-4.34 vs 2.00+/-2.03, P = 0.037).
  • In poorly differentiated cancers (n = 33), the protein levels of ERK-1 and ERK-2 in stage III and IV tumors were higher than those in stage I and II tumors (2.64+/-3.01 vs 1.01+/-0.33, P = 0.022; 2.05+/-1.54 vs 1.24+/-0.40, P = 0.030).
  • Gastric cancer tissues with either lymph node involvement (2.49+/-2.91 vs 1.03+/-0.36, P = 0.023; 1.98+/-1.49 vs 1.24+/-0.44, P = 0.036) or serosa invasion (2.39+/-2.82 vs 1.01+/-0.35, P = 0.022; 1.95+/-1.44 vs 1.14+/-0.36, P = 0.015) expressed higher protein levels of ERK-1 and ERK-2.
  • In Borrmann II tumors, expression of ERK-2 and ERK-3 was increased compared with Borrmann III tumors (2.57+/-1.86 vs 1.23+/-0.60, P = 0.022; 5.50+/-5.05 vs 1.83+/-1.21, P = 0.014).
  • The expression of MEK-1 in gastric cancer cells metastasized to lymph nodes was higher than that of the primary site.
  • CONCLUSION: MAPKs, particularly ERK subclass are overexpressed in the majority of gastric cancers.
  • The overexpression of p38 most likely plays a prominent role in certain morphological subtypes of gastric cancers.
  • MEK-1 is also overexpressed in gastric cancer, particularly in metastatic lymph nodes.
  • Upregulation of MAPK signal transduction pathways may play an important role in tumorigenesis and metastatic potential of gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. MAP Kinase Signaling System / physiology. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655810.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 6; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1
  • [Other-IDs] NLM/ PMC4250727
  •  go-up   go-down


40. Nagahori Y, Nagahori K, Hamaguchi Y, Fukushima T, Masui H, Mogaki M, Abe T: [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1555-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
  • Several chemotherapy regimens combining CPT-11 and CDDP for advanced gastric cancer have been reported to demonstrate high response rates and high incidence of severe toxicity.
  • PATIENTS AND METHODS: Seven patients with histologically-confirmed intestinal type of gastric adenocarcinoma were enrolled in this study.
  • Six patients received combination chemotherapy with CPT-11 and CDDP after the gastrectomy (stage I b: 1, II : 3, III b: 1, IV: 1).
  • CONCLUSION: The combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may achieve a prolonged median survival time in patients with intestinal- type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799911.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


41. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of 980 patients with gastric cancer after surgical resection.
  • BACKGROUND AND OBJECTIVE: Although surgery is the only possible means to cure gastric cancer, the prognosis is often discrepant.
  • The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) published the TNM classification of Malignant Tumors (seventh edition) for gastric cancer recently.
  • This study aimed to use this new edition staging system to investigate the prognostic factors for gastric cancer.
  • METHODS: The clinicopathologic data of 980 patients with gastric cancer treated by surgical resection in our hospital between January 2000 and December 2006 were analyzed retrospectively.
  • The 5-year survival rates for patients with pTNM stage I, II, III, and IV disease classified by the 7th edition staging system were 93.2%, 72.4%, 39.1%, and 5.2%, respectively.
  • CONCLUSION: Compared with the 6th edition system, the new edition of TNM staging system for gastric cancer can accurately predict the survival after operation.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Neoplasm Staging / standards. Stomach Neoplasms
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / classification. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Kimura Y, Taniguchi H, Yano H, Miyazaki S, Nakamura H, Danno K, Kanoh T, Ohnishi T, Tono T, Nakano Y, Kagawa K, Monden T, Imaoka S: [A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2499-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy].
  • We report a case of liver metastasis from gastric cancer that was effectively controlled with stereotactic radiation therapy (SRT).
  • A 77-year-old man underwent total gastrectomy, splenectomy, cholecystectomy and D2 dissection in February 2007 for type 3 gastric cancer in the upper third area that was diagnosed well to moderately differentiated adenocarcinoma and Stage II (T3 (SE) N0 H0 P0 CY0 M0).
  • It is thought that SRT is one of effective treatments for liver metastasis from gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Radiosurgery. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224619.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR: The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg; 2008 Oct;248(4):549-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Surveillance, Epidemiology and End Results (SEER) data indicate that number of lymph nodes removed impacts survival in gastric cancer.
  • METHODS: The study population included 2303 esophageal cancer patients (1381 adenocarcinoma, 922 squamous) from 9 international centers that had R0 esophagectomy prior to 2002 and were followed at regular intervals for 5 years or until death.
  • There were 508 patients with stage I, 853 stage II, and 942 stage III.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Lymph Node Excision / statistics & numerical data

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936567.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Zhao L, Shen ZX, Luo HS, Yu JP: Clinical investigation on coexisting of duodenal ulcer and gastric cancer in China. Int J Clin Pract; 2005 Oct;59(10):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical investigation on coexisting of duodenal ulcer and gastric cancer in China.
  • The aim of this study was to investigate the prevalence of coexistent duodenal ulcer and gastric cancer in China, then to explore the features of clinical manifestations, endoscopy, pathology and possible pathogenesis.
  • 37 cases of coexistent duodenal ulcer and gastric cancer were found.
  • Duodenal ulcer was single in all cases with seven in A1 stage, three in A2 stage, one in H1 stage, one in H2 stage, seven in S1 stage and 18 in S2 stage.
  • 89.2% (33/37) of concurrent gastric cancer were in the corpus and antrum, with 78.1% (29/37) of them belonging to Bormann type II and 87.1% (27/37) being moderately differentiated adenocarcinoma.
  • The coexisting gastric cancer in patients with duodenal ulcer is infrequent but not rare.
  • Helicobacter pylori eradication is recommended in patients with duodenal ulcer to reduce the risk of contaminant gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178981.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Zhang L, Zhao ZS, Ru GQ, Ma J: Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol; 2006 Jul 7;12(25):3970-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
  • METHODS: In situ hybridization and immuno-histochemistry techniques were used to study the expressions of uPA mRNA, uPAR mRNA, VEGF and CD34 protein in 105 gastric carcinoma specimens.
  • The uPA mRNA and uPAR mRNA positive expression rates in infiltrating-type cases (73.7%, 75.4%), stage III-IV (72.1%, 75.4%), vessel invasion (63.2%, 69.9%), lymphatic metastasis (67.1%, 74.4%) and distant metastasis (88.1%, 85.7%) were significantly higher than those of the expanding-type (chi2 = 15.57, P = 0.001; chi2 = 6.91, P = 0.046), stage I-II (chi2 = 19.22, P = 0.001; chi2 = 16.75, P = 0.001), non-vessel invasion (chi2 = 11.92, P = 0.006; chi2 = 14.15, P = 0.002), non-lymphatic metastasis (chi2 = 28.41, P = 0.001; chi2 = 22.5, P = 0.005) and non-distant metastasis (chi2 = 12.32, P = 0.004; chi2 = 17.42, P = 0.002; chi2 = 11.25, P = 0.012; chi2 = 18.12, P = 0.002).
  • The VEGF positive expression rates in infiltrating-type cases (75.4%), stage III-IV (88.5%), vessel invasion (82.9%), lymphatic metastasis (84.3%) and distant metastasis (95.2%) were significantly higher than those of the expanding-type (chi2 = 9.61, P = 0.021), stage I-II (chi2 = 16.66, P = 0.001), non-vessel invasion (chi2 = 29.38, P = 0.001), non-lymphatic metastasis (chi2 = 18.68, P = 0.005), and non-distant metastasis (chi2 = 22.72, P = 0.007; chi2 = 21.62, P = 0.004).
  • CONCLUSION: uPA and uPAR expressions are correlated with enhanced VEGF-induced tumor angiogenesis and may play a role in invasion and nodal metastasis of gastric carcinoma, thereby serving as prognostic markers of gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Neovascularization, Pathologic / metabolism. Receptors, Cell Surface / metabolism. Stomach Neoplasms / metabolism. Urokinase-Type Plasminogen Activator / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 May 15;56(10):2428-33 [8625323.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):179-86 [9583734.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):973-7 [9615749.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Sep;13(9):936-44 [9794194.001]
  • [Cites] Exp Cell Res. 1999 Mar 15;247(2):495-504 [10066377.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):869-74 [10340907.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Nov;26(11):673-7 [15777506.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Cell Biol. 2001 Feb 19;152(4):777-84 [11266468.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6511-6 [11522648.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1784-92 [11557572.001]
  • [Cites] Clin Exp Metastasis. 2002;19(6):527-34 [12405290.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):43-9 [12708473.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4648-55 [12907645.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2866-9 [14669355.001]
  • [Cites] Oncology. 2004;66(3):210-7 [15218312.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1309-12 [2479987.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6827-9 [2119883.001]
  • [Cites] J Biol Chem. 1991 Jul 5;266(19):12752-8 [1829461.001]
  • [Cites] J Cell Physiol. 1992 Feb;150(2):258-63 [1734031.001]
  • [Cites] FEBS Lett. 1993 May 3;322(1):37-40 [8387028.001]
  • [Cites] FEBS Lett. 1994 Apr 25;343(2):103-6 [8168613.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9709-16 [7730348.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1035-9 [7489359.001]
  • [Cites] Clin Exp Metastasis. 1998 Jan;16(1):62-73 [9502078.001]
  • (PMID = 16810742.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ PMC4087704
  •  go-up   go-down


46. Mylonas I, Mayr D, Walzel H, Shabani N, Dian D, Kuhn C, Kunze S, Jeschke U, Friese K: Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res; 2007 Jul-Aug;27(4A):1975-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
  • BACKGROUND AND AIM: Altered mucin 1 (MUC1) secretion patterns have been implicated in several cancerous conditions including gastric, colorectal and breast carcinomas.
  • MUC1 and TF demonstrated a significant (p = 0.006 and p = 0.046, respectively) down-regulation in surgically staged FIGO III/IV compared to FIGO I/II.
  • Additionally, MUC1 and TF were down-regulated in stage III/IV tumors, while a higher binding of gal-1 was observed in stage III/IV tumors, suggesting a substantial role of this antigen in endometrial carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649808.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Mucin-1; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


47. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP: A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol; 2006 Sep;17(9):1404-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
  • BACKGROUND: The aim of the study was to evaluate the efficacy and toxicity of neoadjuvant chemotherapy with intravenous (i.v.) cisplatin and fluorouracil (5-FU), surgery and postoperative intraperitoneal (i.p.) floxuridine (FUdR) and leucovorin (LV) in patients with locally advanced gastric cancer.
  • T stage downstaging (pretreatment LAP versus surgical pathological stage) was seen in 23% of patients.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788003.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA56225
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Chen L, Tian H, Chen J, He ZG, Tao SF, Lokesh G, Peng SY: Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B; 2005 Jan;6(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of gastric stump cancer: a report of 37 cases.
  • OBJECTIVE: To observe the clinicopathological characteristics of gastric stump cancer (GSC) and evaluate the benefits of radical surgery of GSC.
  • Twenty-one cases that received radical resection were analyzed based on the pTMN stage.
  • RESULTS: Most GSC (32/37) was detected in patients who had received Billroth II reconstruction after partial gastrectomy for benign gastric disease.
  • Differentiated adenocarcinoma was the dominant histopathological type (24/37).
  • The postoperative 5-year survival rate of early stage GSC patients (n=9) was significantly higher than advanced stage GSC (n=12) (55.6% vs 16.5%, xL2=11.48, P<0.01).
  • Five-year survival rate of 21 GSC patients with radical resection were 75% (3/4) for stage I, 60% (3/5) for stage II, 14.2% (1/7) for stage III, and 0% (0/5) for stage IV respectively.
  • The median survival time of 21 GSC patients who underwent radical resection was longer than those undergoing palliative operation (43.0 m vs 13.0 m, x L2=36.31, P<0.01), the median survival time of stage IV patients with radical resection was 23.8 months.
  • Even in stage IV GSC, radical resection can still prolong the survival time.
  • It is necessary for the patients with benign gastric diseases who received partial gastrectomy to carry out the endoscopy follow-up, especially in patients with Billroth II reconstruction procedure at 15-20 years.
  • [MeSH-major] Gastrectomy / mortality. Gastric Stump / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2001 Dec;15(12):1488 [11965473.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):580-4 [11995502.001]
  • [Cites] Gastric Cancer. 2002;5(1):23-8 [12021856.001]
  • [Cites] World J Surg. 2003 May;27(5):567-70 [12715225.001]
  • [Cites] Gut. 1987 Aug;28(8):924-8 [3666558.001]
  • [Cites] Gut. 1988 Mar;29(3):298-301 [3356360.001]
  • [Cites] Ann Surg. 1996 Jun;223(6):701-6; discussion 706-8 [8645043.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):299-301 [9058163.001]
  • [Cites] Gut. 1998 Sep;43(3):342-4 [9863478.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):188-94 [10674609.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2197-201 [10928177.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • (PMID = 15593390.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC1390757
  •  go-up   go-down


49. Dalal KM, Woo Y, Kelly K, Galanis C, Gonen M, Fong Y, Coit DG: Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer; 2008;11(4):206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction.
  • BACKGROUND: Gastric cancer patients with positive (+) peritoneal cytology have a prognosis similar to stage IV patients.
  • METHODS: Peritoneal washings were obtained prospectively from 34 patients with gastric adenocarcinoma undergoing staging laparoscopy and 6 patients undergoing laparoscopy for benign disease.
  • RESULTS: Pathologic stages for the gastric cancer patients were: stage I, 9 (27%); stage II, 7 (21%); stage III, 15 (44%); and stage IV, 3 (9%).
  • The four cytology (+) patients were: stage II, 1; stage III, 1; and stage IV, 2.
  • [MeSH-major] Adenocarcinoma / secondary. Peritoneal Cavity / pathology. Peritoneal Neoplasms / secondary. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1850-7 [16721789.001]
  • [Cites] Br J Obstet Gynaecol. 1989 May;96(5):574-9 [2604772.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):678-85 [12576435.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):931-7 [14706632.001]
  • [Cites] Cancer. 1978 Sep;42(3 Suppl):1412-8 [361200.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):435-43 [15048743.001]
  • [Cites] Can J Otolaryngol. 1975;4(1):46-50 [1131725.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1598-605; discussion 1605-6 [17879123.001]
  • [Cites] Gastric Cancer. 2005;8(3):142-8 [16086116.001]
  • [Cites] Chin Med J (Engl). 2004 Aug;117(8):1210-7 [15361297.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4158-63 [10632355.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):244-9 [9841981.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):365-72 [17146744.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3406-11 [9779720.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(2):236-8 [6470030.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Am J Dig Dis. 1978 Feb;23(2):129-33 [623075.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2702-13 [17653801.001]
  • [Cites] Semin Nucl Med. 1975 Jul;5(3):255-62 [1154032.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5 [10518099.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):226-9 [7630168.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Mar;52(3):457-62 [6893991.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 19132482.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Keratin-20; 0 / MUC2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Mucin-2; 0 / RNA, Messenger
  •  go-up   go-down


50. Guo HJ, Wang X, Liu YC, Wan YL, Yin HF, Li T, Zhu J: [Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance]. Beijing Da Xue Xue Bao; 2005 Jun 18;37(3):261-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance].
  • OBJECTIVE: To investigate whether proline-rich tyrosine kinase-2 (Pyk2) is expressed differently in normal gastric mucosas and gastric carcinoma tissues and further to evaluate its significance.
  • METHODS: Expressions of Pyk2 in 59 cases of normal gastric mucosas and 52 cases of gastric carcinoma tissues were analysed by immunohistochemical methods.
  • RESULTS: Immunohistochemical studies showed that the positive rates of Pyk2 protein expression in normal gastric mucosas and gastric carcinoma tissues were 86.44% (51/59) and 19.23% (10/52) respectively.
  • The difference between normal gastric mucosas and gastric carcinoma tissues was statistically significant (P<0.05).
  • The positive rates of Pyk2 expression in highly differentiated gastric carcinoma and moderately/lowly differentiated gastric carcinoma were 47.37% (9/19) and 3.03% (1/33) respectively.
  • Statistically significant differences (P<0.05) were observed in the levels of Pyk2 expression between highly differentiated gastric carcinoma and moderately/lowly differentiated gastric carcinoma.
  • The positive rates of Pyk2 expression at different TNM stages gastric carcinoma were respectively: stage I 66.67% (6/9), stage II 30% (3/10), stage III 3.45% (1/29), stage IV 0% (0/4).
  • The differences were statistically significant [(II+III+IV) v I, chi2=15.767, P<0.05].
  • CONCLUSION: In this study, we demonstrate that Pyk2 is expressed in normal gastric mucosas, whereas its expression declines significantly or almost disappears in gastric carcinoma tissues.
  • The expression of Pyk2 progressively decreases with increasing grade of malignancy and TNM stages of gastric carcinoma.
  • This phenomenon indicates that Pyk2 expression may be involved in the generation and development of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Focal Adhesion Kinase 2 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Gastric Mucosa / metabolism. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968315.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / Focal Adhesion Kinase 2
  •  go-up   go-down


51. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N, Japanese Laparoscopic Surgery Study Group: A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg; 2007 Jan;245(1):68-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Laparoscopic surgery for gastric cancer is technically feasible, but it is not widely accepted because it has not been evaluated from the standpoint of oncologic outcome.
  • We conducted a retrospective, multicenter study of a large series of patients in Japan to evaluate the short- and long-term outcomes of laparoscopic gastrectomy for early gastric cancer (EGC).
  • Histologically, 1212 patients (93.7%) had stage IA disease, 75 (5.8%) had stage IB disease, and 7 (0.5%) had stage II disease (the UICC staging).
  • The 5-year disease-free survival rate was 99.8% for stage IA disease, 98.7% for stage IB disease, and 85.7% for stage II disease.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1800-8 [10430349.001]
  • [Cites] J Am Coll Surg. 1997 Apr;184(4):373-7 [9100682.001]
  • [Cites] Adv Surg. 1999;33:69-93 [10572562.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1647-50 [8932349.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):360-8 [8658220.001]
  • [Cites] Br J Surg. 1997 Nov;84(11):1567-71 [9393281.001]
  • [Cites] J Surg Res. 1999 Jan;81(1):27-32 [9889053.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):49-54 [9923799.001]
  • [Cites] Cancer. 1999 May 15;85(10):2119-23 [10326688.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):217-22 [11227938.001]
  • [Cites] Gastric Cancer. 2001;4(2):93-7 [11706767.001]
  • [Cites] Gastric Cancer. 2001;4(2):98-102 [11706768.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):540-4 [11928051.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1145-9 [12209244.001]
  • [Cites] J Am Coll Surg. 2003 Jan;196(1):75-81 [12517554.001]
  • [Cites] Gastric Cancer. 2003;6(1):64-8 [12673429.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):968-71 [12658427.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):372-8 [12946791.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1440-4 [12820059.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):933-8 [15194075.001]
  • [Cites] Br J Surg. 1990 Dec;77(12):1330-4 [2276010.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):445-50 [8261986.001]
  • [Cites] Surg Laparosc Endosc. 1994 Apr;4(2):146-8 [8180768.001]
  • [Cites] Surg Laparosc Endosc. 1995 Oct;5(5):359-62 [8845979.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • (PMID = 17197967.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1867926
  •  go-up   go-down


52. Abete M, Ronchetti V, Casano A, Pescio G: [Pancreatic fistula after pancreaticoduodenectomy: risk factors and treatment]. Minerva Chir; 2005 Apr;60(2):99-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for surgery were pancreatic head adenocarcinoma (70%), ampullary adenocarcinoma (16.6%), duodenal adenocarcinoma (6.6%) and chronic pancreatitis (6.6%).The personal method of reconstruction after PD consisting of a double Roux-en-Y on the same jejunal loop without interruption of the mesentery and a third anatomical Roux-en-Y to reconstitute the alimentary tract.
  • The gastric stump was anastomosed with the jejunum as a Billroth II-type reconstruction in older patients.
  • Nowadays pancreaticojejunostomy remains the standard technique; pancreaticogastrostomy, occlusion of the pancreatic duct and two-stage pancreaticojejunostomy must be reserved to selected cases.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973216.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


53. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer; 2008;11(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
  • Perioperative chemotherapy in stage II and stage III gastric cancer is now accepted as a standard of care in the Western world.
  • The MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) I study confirmed prospectively the usefulness of early metabolic response evaluation and showed the feasibility of a PET-guided treatment algorithm.
  • In gastric cancer, we have analyzed FDG-PET in a prospective study.
  • In gastric cancer the issue is more complicated, because about 30% of gastric cancers cannot be visualized with sufficient contrast for quantification.
  • Insufficient FDG uptake is mostly associated with diffuse-type gastric cancer with signet ring cells and mucinous content.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):148-55 [16228236.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2029-34 [16330567.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Surg Oncol Clin N Am. 2000 Jan;9(1):97-117, vii-viii [10601527.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1582-8 [16204706.001]
  • [Cites] Ann Surg. 2005 May;241(5):810-7; discussion 817-20 [15849517.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10 ):661-4 [16784672.001]
  • [Cites] Nucl Med Commun. 2004 Aug;25(8):825-31 [15266178.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Gastric Cancer. 2006;9(3):192-6 [16952037.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84 [11142160.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20 [16770582.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18373171.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 42
  •  go-up   go-down


54. Moenig SP, Luebke T, Baldus SE, Schroeder W, Bollschweiler E, Schneider PM, Hoelscher AH: Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases. Anticancer Res; 2005 Mar-Apr;25(2B):1349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases.
  • BACKGROUND: The feasibility and diagnostic reliability of sentinel lymph node biopsy of gastric carcinoma are still unclear and controversial.
  • PATIENTS AND METHODS: To assess the applicability of the sentinel node concept to gastric carcinoma, we retrospectively analyzed the location of metastatic lymph nodes in patients with only one or two lymph node metastases.
  • RESULTS: A total of 135 patients, who underwent gastrectomy with D2 lymphadenectomy for primary gastric adenocarcinoma between 1997 and 2001, were enrolled in this study.
  • Skip metastases were only seen in one patient with cardia carcinoma and lymph node involvement of compartment II (left gastric artery).
  • CONCLUSION: In patients with gastric carcinoma, especially in early stage carcinoma, the phenomenon of skip metastasis is infrequent.
  • Therefore, the sentinel node concept may be feasible in gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865090.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


55. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, Choi SH, Wang LB, Noh SH: Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol; 2008 May;15(5):1464-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection.
  • BACKGROUND: Conflicting results from previous studies on gastric adenocarcinoma (GC) in young patients have led to controversy surrounding the prognosis for young GC patients.
  • However, in regard to T4 invasion, N3 lymph node metastasis, and TNM stage IV, the characteristics of the tumors of young patients were similar to those of middle-aged and elderly patients.
  • Stratified by TNM stage, young patients showed better overall survival at stage I than middle-aged patients, and at stages I, II, and IIIa than elderly patients.
  • Young patients could gain a survival benefit after curative resection with stage I disease.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340495.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • The different surgical approaches according to the tumor origin, localization, and tumor stage are addressed with particular attention to the extent and type of resection and appropriate lymphadenectomy (LAD).
  • While type I tumors benefit from a transthoracic en bloc esophagectomy including a two-field LAD, type II and III tumors can be treated by an extended total gastrectomy with a transhiatal resection of the distal esophagus and LAD of the lower mediastinum and the abdominal D2 compartment.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


57. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, Asmar L: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol; 2008 Jan;19(1):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND: Platinum-based chemotherapy is the standard treatment for advanced gastric cancer (GC).
  • PATIENTS AND METHODS: Patients with untreated stage IV GC or adenocarcinoma of the gastroesophageal junction (AGEJ) received docetaxel 60 mg/m(2) followed by oxaliplatin 130 mg/m(2) on day 1 of each 21-day cycle until progression or unacceptable toxicity.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897959.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7487-88-9 / Magnesium Sulfate; 7S5I7G3JQL / Dexamethasone; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


58. Takada J, Kenno S, Aoki T, Hamada H, Katsuki Y: [A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2326-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
  • The prognosis of most hepatic and lymph node metastases in AFP-producing gastric cancer is poor, and despite the use of multimodal therapy, the average survival period is reported to be approximately one year.
  • Described here is one example in which intra-arterial chemotherapy for simultaneous hepatic metastases in AFP-producing gastric cancer achieved a marked improvement.
  • Distal gastrectomy was performed for Type II gastric cancer.
  • L, type 2, 5.5x2.4 cm, tub 2>por 1, pT2 (MP), int, INF b, ly2, v1, pN1, pPM (-), pDM (-), pH1: stage IV.
  • The AFP level before surgery was 801.4 ng/mL and lowered to 65.8 ng/mL after surgery, AFP-producing gastric cancer and simultaneous hepatic metastases (S4, single lesion) was diagnosed based upon imaging examinations.
  • This suggests the possibility that intra-arterial chemotherapy is an effective treatment method for hepatic metastases in AFP-producing gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / pathology. alpha-Fetoproteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037411.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Siewert JR, Stein HJ, Feith M: Adenocarcinoma of the esophago-gastric junction. Scand J Surg; 2006;95(4):260-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophago-gastric junction.
  • BACKGROUND: The border between the esophagus and stomach gives rise to many discrepancies in the current literature regarding the etiology, classification and surgical treatment of adenocarcinoma arising at the esophago-gastric junction.
  • We have consequently used the AEG-criteria (adenocarcinoma of the esophago-gastric junction) for classification and have based the selection of the surgical approach on the anatomic topographic subclassification.
  • METHODS: In the following we report an analysis of a large and homogeneously classified population of 1602 consecutive patients with adenocarcinoma of the esophago-gastric junction, with an emphasis on the surgical approach, the pattern of lymphatic spread, the outcome after surgical treatment and the prognostic factors.
  • RESULTS: The study confirms the marked differences in sex distribution, associated specialized intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, lymphatic spread, and stage between the three tumor entities.
  • CONCLUSION: The classification of adenocarcinomas of the esophago-gastric junction in three types, AEG type I, type II and type III shows marked differences between the tumor entities and is recommended for selection of a proper surgical approach.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / surgery. Esophageal Neoplasms / classification. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / classification. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249275.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res; 2009 Mar 1;15(5):1821-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.
  • PURPOSE: We determined the expression of mammalian target of rapamycin (mTOR) and its activated form, p-mTOR, in Chinese patients with gastric cancer and its clinical effects and underlying mechanisms.
  • EXPERIMENTAL DESIGN: Tissue microarray blocks containing gastric cancer tissue and matched noncancer gastric tissue specimens obtained from 1,072 patients were constructed.
  • Overexpression of total mTOR protein was significantly correlated with tumor differentiation, T1/T2 tumors, and stage I/II/III disease, whereas p-mTOR overexpression was significantly correlated with lymph node metastasis and all stage disease.
  • The Cox proportional hazards model revealed that the overexpression of p-mTOR, but not total mTOR, was an independent prognostic factor for gastric cancer.
  • The overexpression of p-mTOR also predicted the angiogenic phenotype of human gastric cancer and regulated angiogenesis of gastric cancer cells.
  • CONCLUSIONS: Increased activation of mTOR is frequent in human gastric cancer and overexpression of p-mTOR is an independent prognostic factor, suggesting that mTOR pathway could be a potential target for therapy of this malignancy.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Signet Ring Cell / metabolism. Liver Neoplasms / metabolism. Protein Kinases / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223493.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse
  •  go-up   go-down


61. Cao J, Zuo Y, Lv F, Chen Z, Li J: Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients. J Clin Gastroenterol; 2008 Feb;42(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary small intestinal malignant tumor is relatively uncommon compared to gastric and colorectal cancer.
  • The median OS for all the 20 stage II/III patients who received adjuvant chemotherapy was 28 months, whereas the median OS for the 15 patients who did not receive the therapy was 37 months (P=0.276).
  • The median time to progression for 8 patients with adenocarcinoma who received 5-fluorouracil or platinum-based palliative chemotherapy was 7 months, whereas for the patients who did not receive the therapy it was 3 months (P=0.06).
  • The result of multivariate analyses showed that only the clinical stage was significantly correlated with OS (P<0.001).
  • CONCLUSIONS: The prognosis for small intestinal malignancies is associated with clinical stage, and palliative chemotherapy with a 5-fluorouracil or platinum-based regimen offers a potential benefit to patients with adenocarcinoma.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209587.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 49DFR088MY / Platinum; U3P01618RT / Fluorouracil
  •  go-up   go-down


62. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer; 2009 Mar 10;100(5):782-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between outcomes and localisation of p-mTOR expression in gastric cancer.
  • We evaluated the correlation of mTOR expression with clinicopathological features, outcomes, and the expression of Akt, an upstream regulator of mTOR, in gastric cancer.
  • Tumour samples were obtained from 109 patients with gastric adenocarcinomas who underwent a radical gastrectomy.
  • Cytoplasmic p-mTOR expression positively correlated with the depth of tumour invasion (T1 vs T2-4, P=0.003), involved lymph nodes (P=0.010), and tumour stage (I vs II-IV, P=0.002).
  • Localisation of p-mTOR may play an important role in tumour progression and outcomes in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Protein Kinases / metabolism. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2008 Oct 1;17(19):2934-48 [18614546.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Feb;3(2):295-304 [12020063.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3127-34 [12115344.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28127-34 [12000755.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] APMIS. 2003 Dec;111(12):1105-13 [14678019.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2846-50 [15102693.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6779-88 [15501954.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2053-9 [15240509.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2930-6 [15837744.001]
  • [Cites] Adv Cancer Res. 2005;94:29-86 [16095999.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):376-80 [15900596.001]
  • [Cites] Cell Mol Biol Lett. 2005;10(3):479-98 [16217558.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7455-64 [16288292.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7357-63 [16407298.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):933-9 [16788754.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4309-16 [16963731.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1803-10 [17230506.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1545-52 [17442998.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2311-9 [18390971.001]
  • [Cites] J Clin Pathol. 2008 Aug;61(8):909-13 [18474542.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • (PMID = 19223902.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Oncogene Protein v-akt
  • [Other-IDs] NLM/ PMC2653759
  •  go-up   go-down


63. Lello E, Furnes B, Edna TH: Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncol; 2007;46(3):308-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years.
  • The aim of this study was to evaluate the outcome for gastric cancer patients treated at a medium sized Norwegian hospital.
  • The medical journals of all 356 patients with gastric cancer treated at Levanger Hospital from 1980 to 2004 were retrospectively analysed.
  • Estimated overall 5-year survival was closely related to stage: 91% (95% C.I.
  • 74-100) in stage 1A, 64% (95% C.I.
  • 53-74) in stage 1B, 27% (95% C.I.
  • 10-44) in stage II, 18% (95% C.I.
  • 4-32) in stage IIIA, and none in stages IIIB and IV.
  • [MeSH-major] Adenocarcinoma / mortality. Hospitals, County. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450465.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


64. Hartwig W, Strobel O, Schneider L, Hackert T, Hesse C, Büchler MW, Werner J: Fundus rotation gastroplasty vs. Kirschner-Akiyama gastric tube in esophageal resection: comparison of perioperative and long-term results. World J Surg; 2008 Aug;32(8):1695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fundus rotation gastroplasty vs. Kirschner-Akiyama gastric tube in esophageal resection: comparison of perioperative and long-term results.
  • The aim of the present study was to compare the safety of FRG vs. the conventional Kirschner-Akiyama gastric tube in a large prospective clinical series.
  • Tumor type was squamous cell carcinoma in 51 patients and adenocarcinoma (AEG types I and II) in 60 patients.
  • There were no differences between the reconstruction groups with respect to age, gender, tumor type, neoadjuvant treatment, and tumor stage.
  • CONCLUSION: This clinical series is the first to compare FRG and conventional gastric tube reconstruction after esophagectomy in esophageal cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 Aug;226(2):169-73 [9296510.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):1185-90 [16181838.001]
  • [Cites] Am J Surg. 1979 May;137(5):597-602 [453454.001]
  • [Cites] Surgery. 1996 Sep;120(3):542-6 [8784409.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jun;15(6):769-73 [10431857.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Thorac Cardiovasc Surg. 1992 Aug;104(2):395-400 [1495302.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Surgery. 1986 May;99(5):614-22 [3704918.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):212-7 [11869322.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Dig Surg. 2002;19(2):92-8 [11978992.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Apr;7(2):75-8 [11371275.001]
  • [Cites] J Am Coll Surg. 1996 Mar;182(3):241-5 [8603244.001]
  • [Cites] World J Surg. 1997 Nov-Dec;21(9):992-7 [9361516.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):893-906 [16997168.001]
  • [Cites] Br J Surg. 1976 Mar;63(3):206-9 [1260249.001]
  • [Cites] Am J Surg. 1993 Feb;165(2):273-6 [8427411.001]
  • [Cites] Eur J Surg. 2001 Feb;167(2):110-4 [11266249.001]
  • [Cites] Ann Thorac Surg. 1995 Aug;60(2):261-6; discussion 267 [7646084.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):754-61 [12900366.001]
  • [Cites] Arch Surg. 2005 Jan;140(1):33-9 [15655203.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1125-8 [11571946.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):803-12; discussion 812-4 [14631217.001]
  • [Cites] Ann Thorac Surg. 1992 Dec;54(6):1110-5 [1449294.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):68-75 [15213620.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):177-83 [12170022.001]
  • [Cites] Br J Surg. 1997 Jan;84(1):126-8 [9043476.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):241-6 [17245177.001]
  • (PMID = 18553046.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF: Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol; 2007 Feb;14(2):306-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.
  • INTRODUCTION: Adequate staging of gastric cancer requires examination of at least 15 lymph nodes.
  • METHODS: A prospectively maintained database identified 366 patients with Siewert types II and III adenocarcinoma of the GEJ who underwent R0 resection without neoadjuvant therapy at a single institution.
  • Multivariable analysis of adequately staged patients found the number of positive lymph nodes, T stage, and lymphovascular invasion to be independent prognostic factors for overall survival (OS).
  • For inadequately staged patients only the number of positive lymph nodes and T stage were independent prognostic factors.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Lymph Node Excision / standards. Lymph Nodes / pathology. Stomach Neoplasms / pathology


66. Pérez Pereyra J, Frisancho Velarde O: [Esophageal cancer: epidemiological, clinical, and pathological characteristics at Hospital Rebagliati (Lima)]. Rev Gastroenterol Peru; 2009 Apr-Jun;29(2):118-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the most frequent types were epidermoid carcinoma (82.1%) and adenocarcinoma (16%).
  • Esophageal resection and gastric pull-up were only feasible in 25% of patients; out of these 11% were at stage I, 37% at stage II, 37% at stage III, and 15% at stage IV.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609326.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


67. Kassam Z, Mackay H, Buckley CA, Fung S, Pintile M, Oza A, Brierley J, Swallow C, Cummings B, Knox JJ, Kim J, Wong R, Siu L, Feld R, Ringash J: Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study. Curr Oncol; 2010 Aug;17(4):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study.
  • OBJECTIVE: This phase I study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5FU) and concurrent radiation therapy (RT) in patients after complete resection of gastric adenocarcinoma.
  • METHODS: Patients with resected stage IB to IV (M0) gastric adenocarcinoma were treated with 12 weeks of infusional 5FU (200 mg/m(2) daily) and with RT (45 Gy in 25 fractions starting on day 16).
  • CONCLUSIONS: Cisplatin was well tolerated in combination with infusional 5FU and RT, showing promising activity in the adjuvant treatment of gastric cancer.
  • Infusional 5FU 200 mg/m(2) daily for 12 weeks with cisplatin 40 mg/m(2) in weeks 1, 3, 5, and 7 and with concurrent RT 45 Gy in 25 fractions, starting at day 16, is being explored in a phase II study at our institution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] ANZ J Surg. 2004 Nov;74(11):951-6 [15550081.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):777-82 [9128951.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):277-84 [8996153.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1433-8 [14562013.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1373-7 [12954575.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1069-75 [12419433.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):712-6 [17848909.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):713-9 [16626887.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):603-7 [16489675.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):732-8 [15978742.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1326-33 [15919686.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(2):CD004064 [15846694.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • (PMID = 20697512.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2913826
  • [Keywords] NOTNLM ; 5-fluorouracil / Adjuvant therapy / chemoradiation / cisplatin / gastric cancer / phase i study
  •  go-up   go-down


68. Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H, Miwa K, Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC): A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol; 2006 Aug;36(8):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
  • In this randomized multicenter Phase III study, patients with curatively resected Stage II/IIIA gastric cancer were assigned to postoperative adjuvant therapy with an oral fluoropyrimidine S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months) or S-1 combined with an oral biological response modifier PSK (the same regimen of S-1 plus daily PSK for 12 months).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Immunologic Factors / administration & dosage. Immunotherapy. Oxonic Acid / administration & dosage. Proteoglycans / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803844.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00216034
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Immunologic Factors; 0 / Proteoglycans; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 66455-27-4 / krestin
  •  go-up   go-down


69. Ohi S, Takahashi N, Ninomiya K, Nakajima M, Hashimoto H, Tachibana T, Yanaga K, Ishikawa H: Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma. Hum Cell; 2007 Feb;20(1):15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma.
  • We successfully established a spontaneously cisplatin-resistant tumor cell line (designated as IGSK-1) derived from original gastric carcinoma.
  • The histopathological diagnosis was gastric poorly differentiated adenocarcinoma accompanied with metastatic foci in lymph nodes, pT3, N2 M0, stage IIIB.
  • Spontaneously cisplatin-resistant gastric carcinoma cell line secreted gastrin and somatostatin is very important material for chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Stomach Neoplasms / pathology


70. Euanorasetr C, Lertsithichai P: Results of D2 gastrectomy for gastric adenocarcinoma: 10-year experience in Thai patients. J Med Assoc Thai; 2007 Feb;90(2):291-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of D2 gastrectomy for gastric adenocarcinoma: 10-year experience in Thai patients.
  • BACKGROUND: The therapeutic value of D2 gastrectomy in the curative treatment of gastric adenocarcinoma is controversial outside Japan.
  • MATERIAL AND METHOD: The authors retrospectively reviewed the medical records of 97 patients with gastric adenocarcinoma who underwent curative D2 gastrectomy between October 1995 and September 2005.
  • The 5-year disease-free survival rate for each TNM stage was 100% for stages IA and IB, 75% for stage II, 78% for stage IIIA, 28% for stage IIIB and 4% for stage IV.
  • CONCLUSION: The D2 gastrectomy can be performed with low morbidity and mortality, and may increase the cure rate and survival of Thai gastric adenocarcinoma patients, at least in experienced centers.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375634.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


71. Isgüder AS, Nazli O, Tansug T, Bozdag AD, Onal MA: Total gastrectomy for gastric carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for gastric carcinoma.
  • BACKGROUND/AIMS: Gastric cancer is one of the most common organ cancers all around the world and surgical resection is essential for treatment.
  • Total gastrectomy is the procedure of choice for treatment of proximal gastric cancer.
  • METHODOLOGY: Thirty-eight gastric cancer patients underwent total gastrectomy in the Third Surgical Clinic of Izmir Ataturk Training and Research Hospital between 1996 and 2001.
  • Age, gender, location of the tumor, histopathological findings, TNM stage, type of anastomosis, operation time, blood transfusions, oral food intake, postoperative hospital stay, morbidity, mortality both early and late, and survival rate were evaluated.
  • Histological types were adenocarcinoma (97.4%), and squamous cell carcinoma (2.6%).
  • TNM stages were: stage la 2.6%, stage II 7.9%, stage IIIa 39.5%, stage IIIb 42.1%, and stage IV 7.9%.
  • Gastric tubes were removed on the fourth postoperative day.
  • 89.5% of our cases were stage III or IV resulting in a low survival rate.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


72. Díaz de Liaño A, Yárnoz C, Aguilar R, Artieda C, Ortiz H: [Morbidity and mortality in gastrectomy with D2 lymphadenectomy in a specialised unit]. Cir Esp; 2008 Jan;83(1):18-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the morbidity and mortality in a series of patients with gastric cancer treated by gastrectomy and D2 lymphadenectomy, and compare these results with those published by centres with notable experience.
  • PATIENTS AND METHOD: A descriptive and prospective study on a series of 126 consecutive patients with gastric cancer treated by gastrectomy and D2 lymphadenectomy.
  • The stages, according to the AJCC, were: stage 0: 4.8%, IA: 17.5%, IB: 22.2%, II: 10.3%, IIIA: 16.7%, IIIB: 9.5%, and stage IV: 19%.
  • CONCLUSIONS: Patients with gastric cancer, even with associated risk factors, can be treated by gastrectomy and D2 lymphadenectomy with similar morbidity and mortality rates to those centres with more experience, due to a great extent to sub-specialising in this surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Lymph Node Excision. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208744.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Friedrich-Rust M, Jaeger C, Gossner L, May A, Günter E, Stolte M, Ell C: [Early duodenal adenocarcinoma arising in gastric metaplasia treated by endoscopic resection]. Z Gastroenterol; 2006 Apr;44(4):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early duodenal adenocarcinoma arising in gastric metaplasia treated by endoscopic resection].
  • Most duodenal carcinomas are diagnosed at a more advanced stage.
  • This report describes the case of a 59-year-old lady with an early duodenal adenocarcinoma diagnosed at check-up gastroduodenoscopy in an outpatient clinic who was referred to us for further investigation and management.
  • Histopathological examination revealed the rare entity of an early duodenal carcinoma arising from incomplete-type gastric metaplasia in the duodenum.
  • In summary, the presented paper describes a case of successful endoscopic treatment of an early duodenal carcinoma arising from incomplete gastric metaplasia.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenal Neoplasms / surgery. Endoscopy, Gastrointestinal. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625461.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Nakamura R, Saikawa Y, Wada N, Yoshida M, Kubota T, Kumai K, Kitajima M: Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience. Int J Clin Oncol; 2007 Aug;12(4):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience.
  • BACKGROUND: Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery.
  • METHODS: Records for 83 patients, who were treated between 1991 and 2004, were evaluated for survival and stage, treatment, and clinicopathological factors.
  • RESULTS: Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease.
  • The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days.
  • For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days.
  • [MeSH-major] Adenocarcinoma, Scirrhous / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):209-14 [9142381.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):112-7 [7844980.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jul;175(1):13-6 [1621194.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):381-6 [12579276.001]
  • [Cites] Surgery. 1989 Oct;106(4):758-62; discussion 762-3 [2552599.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):194-200 [9236929.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Dig Dis Sci. 1992 May;37(5):757-63 [1563320.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8 [15783058.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Am J Surg. 2004 Sep;188(3):327-32 [15450843.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:40-4 [12775019.001]
  • [Cites] Intern Med. 1996 Dec;35(12):930-6 [9030989.001]
  • (PMID = 17701009.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol; 2006 Aug 20;24(24):3953-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
  • PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal.
  • PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible.
  • Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage III).
  • CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting.
  • With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921048.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


76. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest; 2008 May;26(4):344-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues(0, 30%, 20% and 0, respectively, P < 0.01).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05).
  • The expression of Topo-II was associated with increasing differentiated degree (33.3%, 69.7 and 80.7%, P < 0.01).
  • No significant differences with Topo-II expression were found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs 72.4%, P > 0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis (with vs without metastasis, 70.0% vs 41.4%, P < 0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0, 26.1, 7.24, 5.8, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II alpha and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Glutathione S-Transferase pi / analysis. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443954.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


77. del Casar JM, Corte MD, Alvarez A, García I, Bongera M, González LO, García-Muñiz JL, Allende MT, Astudillo A, Vizoso FJ: Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol; 2008 Feb;134(2):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance.
  • BACKGROUND: Lymphatic and/or blood vessel tumoral invasion (LBVI) is a common histopathologic finding of gastric carcinomas, which could make it an additional cost efficient marker and help in the detection of patients at risk for recurrence.
  • MATERIALS AND METHODS: The subjects of this study were 144 patients with primary gastric adenocarcinoma, who consecutively underwent surgery.
  • The presence of LBVI correlated significantly with tumor stage, lymph node involvement, surgical resectability, histological type and histological grade, being present in a higher percentage among II-IV tumor stage (P = 0.0001), poorly differentiated (P = 0.01), diffuse type (P = 0.009), R1-R2 (P = 0.002) and lymph node-positive (P = 0.005) tumors.
  • CONCLUSION: LBVI provides additional useful information that could be applied to identify gastric cancer patients at risk for recurrence, who might be candidates for further adjuvant therapies.
  • [MeSH-major] Adenocarcinoma / secondary. Blood Vessels / pathology. Lymph Nodes / pathology. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] Ann Surg Oncol. 1999 Apr-May;6(3):286-9 [10340888.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):5-11 [11525306.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):766-72 [8795580.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):325-8 [8472141.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4324-7 [10969769.001]
  • [Cites] Gastric Cancer. 1998 Mar;1(2):125-133 [11957056.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):44-50 [10763140.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Br J Cancer. 2005 Sep 19;93(6):688-93 [16136051.001]
  • [Cites] Breast Cancer Res Treat. 1991 Jan-Feb;17(3):211-9 [1645606.001]
  • [Cites] Int J Biol Markers. 2003 Jul-Sep;18(3):200-6 [14535591.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):306-12 [15273556.001]
  • [Cites] Int Surg. 1999 Oct-Dec;84(4):331-6 [10667813.001]
  • [Cites] Int Surg. 2000 Oct-Dec;85(4):286-90 [11589593.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1015-8 [8402053.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1343-52 [13679442.001]
  • [Cites] Oncology. 2005;69 Suppl 3:4-10 [16301830.001]
  • [Cites] Int J Biol Markers. 2001 Jan-Mar;16(1):37-44 [11288953.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):64-73 [16371738.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1723-8 [17486129.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):550-5 [8299076.001]
  • [Cites] Int J Biol Markers. 2004 Oct-Dec;19(4):268-74 [15646832.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):318-24 [15028316.001]
  • [Cites] Surg Today. 2003;33(2):95-100 [12616368.001]
  • [Cites] Cancer Treat Res. 1996;82:235-53 [8849954.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):203-7 [1879965.001]
  • [Cites] Surgery. 2003 Oct;134(4):720-7; discussion 727-9 [14605635.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):16-21 [15048675.001]
  • [Cites] Jpn J Surg. 1990 Sep;20(5):545-52 [2243447.001]
  • [Cites] J Chir (Paris). 1998 Oct;135(4):148-54 [9827393.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):994-8 [12439912.001]
  • [Cites] CA Cancer J Clin. 1993 Jan-Feb;43(1):7-26 [8422609.001]
  • [Cites] Surgery. 1995 Apr;117(4):380-5 [7716718.001]
  • [Cites] Surgery. 1990 Feb;107(2):140-8 [1689080.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):562-7 [12095972.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):828-35; discussion 835-7 [12796579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem J. 1969 Jun;113(2):299-305 [4185494.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4A):2351-5 [11724292.001]
  • [Cites] Ann Surg Oncol. 1995 Jul;2(4):308-13 [7552619.001]
  • [Cites] Eur Surg Res. 1997;29(1):35-41 [9013104.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • (PMID = 17628829.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


78. Butte JM, Becker F, Visscher A, Waugh E, Meneses M, Court I, Parada H, DE LA Fuente H: [Adenocarcinoma of the esophagogastric junction: retrospective analysis of 39 patients]. Rev Med Chil; 2010 Jan;138(1):53-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the esophagogastric junction: retrospective analysis of 39 patients].
  • BACKGROUND: The long-term survival of adenocarcinoma of the esophago-gastric junction is poor and depends on the possibility of performing a complete surgical excision and the absence of lymph node involvement.
  • AIM: To report surgical results and survival of patients with adenocarcinoma of the esophago-gastric junction.
  • MATERIAL AND METHODS: Retrospective review of medical records of patients with adenocarcinoma of the esophago-gastric junction, subjected to a curative surgical procedure between 2000 and 2008.
  • Tumor stage was determined using TNM and Siewert pathological classifications.
  • According to Siewert classification, seven patients had type I, six type II and 26 type III tumors.
  • According to postoperative staging, five patients were in stage I, 12 in stage II, nine in stage III and 13 in stage IV.
  • Well differentiated and stage I tumors had a better survival.
  • CONCLUSIONS: Among patients with adenocarcinoma of the esophago-gastric junction, type III tumors, lymph node involvement and vascular permeations are associated with a lower survival.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / mortality. Esophagogastric Junction / surgery. Gastrectomy / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361151.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


79. Zhao ZS, Wang YY, Ye ZY, Tao HQ: Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res; 2009 Dec;15(4):589-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of tumor-related molecular expression in gastric carcinoma.
  • In order to identify reliable molecular markers for prognostic prediction in gastric carcinoma, we evaluated the expression of six molecular markers, namely bFGF, IGF-2, HGF, MMP-9, integrin beta3 and uPA in gastric cancer.
  • There was a significant correlation between the expression of these markers and the depth of tumor invasion, vessel invasion, lymph node and distant metastasis, TNM stage and microvessel density.
  • Multivariate analysis showed that abnormal expression of bFGF, MMP-9 and uPA, as well as depth of invasion, lymph node and distant metastasis and TNM stage were independently related to poor prognosis of gastric cancer.
  • MMP-9, bFGF and uPA are potential candidates for development as clinically applicable molecular prognostic markers for gastric carcinoma, and may be effective therapeutic targets for the disease in the future.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Fibroblast Growth Factor 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Stomach Neoplasms / diagnosis. Urokinase-Type Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Hepatocyte Growth Factor / metabolism. Humans. Insulin-Like Growth Factor II / metabolism. Integrin beta3 / metabolism. Male. Middle Aged. Multivariate Analysis. Neovascularization, Pathologic. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2257-63 [11677116.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2738-47 [17687613.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):149-54 [16847924.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):676-9 [16438890.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Clin Chim Acta. 2005 Apr;354(1-2):91-9 [15748604.001]
  • [Cites] J Korean Med Sci. 2006 Apr;21(2):272-8 [16614513.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1126-32 [11706074.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):529-38 [12761886.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Jul;28(1):89-97 [15177237.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1215-20 [18355442.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1591-5 [17708308.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):568-73 [10228863.001]
  • [Cites] Neurosci Lett. 2007 Apr 24;417(1):1-5 [17386975.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Eur J Cancer Prev. 2007 Dec;16(6):517-27 [18090124.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):43-9 [12708473.001]
  • [Cites] Exp Mol Med. 2005 Jun 30;37(3):213-9 [16000876.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] World J Gastroenterol. 2003 May;9(5):899-904 [12717827.001]
  • (PMID = 19294533.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin beta3; 103107-01-3 / Fibroblast Growth Factor 2; 67256-21-7 / Hepatocyte Growth Factor; 67763-97-7 / Insulin-Like Growth Factor II; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


80. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, Yoshida K, Yasui W: Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer; 2009 Nov 15;125(10):2383-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients.
  • Gastric cancer (GC) is 1 of the most common human cancers.
  • Olfactomedin 4 staining was observed more frequently in stage I/II cases than in stage III/IV cases.
  • In patients with stage I GC, the sensitivity of serum olfactomedin 4 (25%) and Reg IV (35%) was superior to that of CA19-9 (5%) or CEA (3%).
  • Furthermore, in patients with stage I GC, the combination of olfactomedin 4 and Reg IV elevated the diagnostic sensitivity to 52%.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Carcinoma, Adenosquamous / blood. Granulocyte Colony-Stimulating Factor / blood. Lectins, C-Type / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670418.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Lectins, C-Type; 0 / OLFM4 protein, human; 0 / REG4 protein, human; 0 / RNA, Messenger; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


81. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • The prognosis of locally advanced gastric cancer remains poor.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • These results have a profound effect on the treatment of patients presenting with stage II or stage III disease.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2885-94 [16929515.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14 (7):2012-8 [18381939.001]
  • [Cites] Chirurg. 2006 Nov;77(11):971-80 [17066269.001]
  • [Cites] Chirurg. 2007 Sep;78(9):792-801 [17676284.001]
  • [Cites] Gastric Cancer. 2005;8(1):1-5 [15747167.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1017-25 [19189186.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Chirurg. 2006 Mar;77(3):227-35 [16511688.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5095-102 [17785563.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2008;11(1):1-9 [18373171.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4):593-601 [17903735.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Chirurg. 1999 May;70(5):520-9 [10412596.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


82. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E: Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg; 2007 Jun;94(6):737-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and prognosis of gastric cancer in young European adults.
  • BACKGROUND: The aims of this study were to define the clinicopathological features and prognosis of gastric cancer in young European adults.
  • METHODS: Between 1990 and 2004, 603 patients with gastric cancer were enrolled in a prospective database.
  • RESULTS: In the younger group there were significantly more women (57 versus 36.3 per cent; P = 0.004), Laurén diffuse-type carcinomas (73 versus 42.7 per cent; P < 0.001), N2-3 lymph node metastases (59 versus 38.9 per cent; P = 0.005), stage IV disease (49 versus 35.7 per cent; P = 0.085) and resections that were non-curative (36 versus 18.5 per cent; P = 0.007) than in the older patients.
  • Unfavourable prognostic factors associated with poor 5-year survival were the degree of gastric wall invasion (T3-4 versus T1-2; P < 0.001), lymph node invasion (positive versus negative; P < 0.001), disease stage (III-IV versus I-II; P < 0.001) and curability of resection (non-curative versus curative; P < 0.001).
  • CONCLUSION: Gastric cancer in young adults tends to be more advanced; however, when matched for stage, the prognosis does not differ from that of older patients.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 British Journal of Surgery Society Ltd.
  • (PMID = 17330827.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Garrido M, Bustos M, Orellana E, Madrid J, Galindo H, Sánchez C, Pimentel F, Guzmán S, Ibáñez L, Butte JM, Alvarez M, Besa P: [Postoperative radio-chemotherapy in locally advanced gastric cancer]. Rev Med Chil; 2008 Jul;136(7):844-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative radio-chemotherapy in locally advanced gastric cancer].
  • BACKGROUND: Overall 5 years survival for surgically excised gastric cancer is 30%.
  • AIM: To assess treatment results and toxicity in patients with surgically excised gastric cancer, treated with adjuvant radiotherapy and concomitant continuous 5-Fluorouracil (5-FU).
  • MATERIAL AND METHODS: Forty one patients aged 32 to 73 years (29 males) with stage II-IVA gastric cancer, subjected to a total or subtotal gastrectomy and D2 nodal dissection between 1997 to 2006, were studied.
  • They received adjuvant radiotherapy to the gastric bed and draining nodes in a total dose of 50.4 Gy in 28 fractions and chemotherapy with continuous infusion 5-FU, 200 mg/m(2)/day.
  • RESULTS: Eighteen patients were in stage II, 10 in stage IIIA, nine in stage IIIB and four in stage IVA.
  • CONCLUSIONS: Adjuvant radio-chemotherapy improved overall survival in gastric cancer, compared to historical controls subjected only to surgical treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949159.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


84. Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg; 2009 Jan;96(1):66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma.
  • BACKGROUND: Insulin-like growth factor II mRNA-binding protein (IMP) 3 is expressed in embryonic tissues and multiple cancers.
  • The aim was to establish the prognostic value of IMP-3 expression in gastric adenocarcinoma.
  • METHODS: IMP-3 expression in resected gastric adenocarcinomas was analysed by immunohistochemistry.
  • IMP-3-positive tumours were associated with poorer 5-year survival than negative tumours at all stages (stage I, 82 versus 97 per cent; stage II, 55 versus 78 per cent; stage III and IV, 11 versus 25 per cent; P = 0.005, P = 0.033 and P = 0.036 respectively).
  • Multivariable analysis identified IMP-3 (hazard ratio (HR) 1.93), depth of tumour invasion (HR 3.69, 9.77 and 10.69 for pathological tumour stage (pT) 2, pT3 and pT4 respectively versus pT1), and lymph node metastasis (HR 1.57, 3.29 and 3.40 for pathological node stage (pN) 1, pN2 and pN3 respectively versus pN0) as independent prognostic factors.
  • CONCLUSION: IMP-3 expression correlates with the metastatic potential of gastric adenocarcinoma and is an independent prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19109797.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Messenger
  •  go-up   go-down


85. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K, Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer; 2010 Apr;46(6):1101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.
  • BACKGROUND: Survival of gastric cancer in the Western world remains poor.
  • We conducted a retrospective population-based study to evaluate trends in incidence, treatment and outcome of gastric adenocarcinoma.
  • METHODS: All patients diagnosed with gastric adenocarcinoma during 1990-2007 in the Dutch Eindhoven Cancer Registry area were included (n=4,797).
  • Stage distribution worsened over time among patients with cardia (stages I and II: 32% in 1990-1993 and 22% in 2006-2007, p=0.005) and non-cardia (stage IV: 33% in 1990-1993 and 40% in 2006-2007, p=0.0003) cancer.
  • Age and stage had significant influence on survival after stratification for tumour localisation.
  • After adjustments for relevant factors (i.e. stage), the risk of death decreased since the late 90s for patients with a cardia tumour (hazard ratio 0.8, p=0.01).
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219351.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


86. Lee J, Lee K, Kim W: Duodenal stump cancer after Billroth-II distal gastrectomy for gastric cancer. Gastric Cancer; 2009;12(2):118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal stump cancer after Billroth-II distal gastrectomy for gastric cancer.
  • However, metachronous or even recurrent cancer at the duodenal stump following Billroth II type distal gastrec tomy for gastric cancer is extremely rare and, to our knowledge, has not yet been reported.
  • A 68-year-old man underwent Billroth II distal gastrectomy with D2 lymph node dissection for an advanced gastric cancer.
  • At that time the tumor stage was T2bN3M0, with 44 of 78 retrieved lymph nodes showing metastasis.
  • A polypoid tumor that bled easily when touched was found at the end of the afferent loop of the duodenal stump by gastrofiberscopic examination, and it was proven to be an adenocarcinoma by endoscopic biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Gastroenterostomy. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2002 May-Jun;34(5):533-5 [11960064.001]
  • [Cites] J Surg Oncol. 2008 Aug 1;98(2):106-10 [18452218.001]
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] Radiographics. 2006 Jan-Feb;26(1):143-56 [16418249.001]
  • [Cites] Am J Surg. 2008 Jul;196(1):19-22 [18417082.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] Surg Today. 2000;30(8):735-8 [10955739.001]
  • [Cites] Am Surg. 1995 Apr;61(4):371-6 [7893109.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] Oncology. 2003;65(2):113-7 [12931016.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1070-4; discussion 1074-5 [10982512.001]
  • [Cites] Clin Radiol. 2003 Mar;58(3):215-21 [12639527.001]
  • (PMID = 19562467.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Chang HC, Chen YL, Chan CP, Yeh KT, Kuo SJ, Ko CJ, Fang HY: Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients. Dig Dis Sci; 2009 Feb;54(2):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients.
  • This study evaluated the correlation between clinicopathological data and DDH expression and the prognostic significance of DDH expression in patients with resected gastric cancer.
  • Between January 1998 and September 2004, we retrospectively enrolled 81 patients who received surgical treatment for gastric cancer.
  • The relationship between DDH expression and clinicopathological data (age, gender, histological type, stage) was analyzed by chi-square analysis.
  • Of patients with overexpressed DDH, 13% had stage I, 24% had stage II, 52% had stage III, and 78% had stage IV tumors.
  • Thus, DDH expression may be useful in identifying high-risk gastric cancer patients and distinguishing future candidates for curative and palliative treatment.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Oxidoreductases / metabolism. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1992 May 1;205(3):1155-62 [1576998.001]
  • [Cites] Chem Biol Interact. 1993 Oct;89(1):1-34 [8221964.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):515-9 [11956619.001]
  • [Cites] Biochem Pharmacol. 1992 Jul 22;44(2):341-9 [1642648.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):717-23 [15375490.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15035-43 [11842089.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1005-14 [17972143.001]
  • [Cites] Biochemistry. 1998 May 12;37(19):6781-90 [9578563.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):603-8 [17943730.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):301-7 [15138708.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5112-7 [16951228.001]
  • [Cites] Gastric Cancer. 2004;7(4):196-201; discussion 201-203 [15616767.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2727-31 [11289154.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):246-51 [15197778.001]
  • [Cites] Scand J Gastroenterol. 2007 Sep;42(9):1070-2 [17710672.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):271-6 [12579257.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):110-7 [15790446.001]
  • [Cites] Gastric Cancer. 2005;8(2):64-70 [15864711.001]
  • (PMID = 18600452.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
  •  go-up   go-down


88. Madani K, Zhao R, Lim HJ, Casson AG: Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg; 2010 Jun;37(6):1427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.
  • OBJECTIVE: This study evaluates the clinical significance of p53 mutations in oesophageal adenocarcinoma (EADC).
  • Strict clinicopathologic criteria were used to define primary EADC (Type I), excluding gastric cardia adenocarcinoma (Type II).
  • Conventional predictors of reduced OS included advanced pathological tumour-node-metastasis (pTNM) stage (P<0.0001) and number of involved lymph nodes (0, 1-3, >3; P<0.0001).
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Genes, p53. Mutation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20227286.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


89. Ito S, Kodera Y, Mochizuki Y, Kojima T, Nakanishi H, Yamamura Y: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. World J Surg; 2010 Sep;34(9):2083-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
  • BACKGROUND: We have previously reported the molecular detection of peritoneal micrometastases in patients with gastric cancer by quantifying carcinoembryonic antigen (CEA) mRNA in the peritoneal washes.
  • METHODS: CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy.
  • Overall survival, the primary endpoint of this phase II trial, was compared with the historical control, which is comprised of CEA mRNA (+) patients who were not given postoperative chemotherapy.
  • RESULTS: A total of 32 patients with CEA mRNA (+) gastric cancer were enrolled.
  • CONCLUSIONS: S-1 monotherapy, which significantly reduced risk for recurrence in stage II/III gastric carcinoma in another phase III trial, seems not to be as effective in eradicating free cancer cells in the abdominal cavity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Feb;35(2):468-9; author reply 470-1 [20857104.001]
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):960-3 [17591103.001]
  • [Cites] Gastric Cancer. 2008;11(4):206-13 [19132482.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):687-92 [9310142.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):411-7 [11008202.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):653-9 [9815733.001]
  • [Cites] Langenbecks Arch Surg. 2005 Sep;390(5):430-41 [15991048.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):986-92 [16205696.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S32-6 [10357556.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):581-9 [11520161.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):361-8 [16428473.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2609-16 [18451223.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 20379713.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


90. Carlomagno C, Insabato L, Bifulco G, De Placido S, Lauria R: Ovarian metastasis following gallbladder carcinoma: a case report. Eur J Gynaecol Oncol; 2010;31(2):219-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most metastatic ovarian tumors originate from the gastrointestinal tract, mainly colorectal, gastric, pancreatic; the gallbladder is a very rare source of ovarian metastases.
  • CONCLUSION: The interest of this case lies in the long progression-free survival, the venous thromboembolism syndrome that preceded by a few months the diagnosis of the ovarian mass and the discrepancy between the radiologic and the laparoscopic stage assessment.
  • [MeSH-major] Adenocarcinoma / secondary. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527247.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


91. Xu DK, Zhao P, Wang CF, Shao YF, Lin HW, Tian YT: [Clinicopathological characteristics and prognosis of remnant stomach cancer--report of 45 cases]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):852-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their initial operation modes of these patients were Billroth II subtotal gastrectomy in 40 patients, Billroth I subtotal gastrectomy in 4 and proximal subtotal gastrectomy in 1.
  • Of these 45 patients, 28 had lesion at anastomotic site, 9 in the gastric cardia and 8 in other locations; 19 had radical resection, 16 palliative resection and 10 exploration alone except one who had an anastomosis of remnant stomach with the jejunum.
  • The histology types included: 1 un-differentiated adenocarcinoma, 36 poorly-differentiated adenocarcinoma, 7 moderately-differentiated adenocarcinoma and 1 well-differentiated adenocarcinoma.
  • The 5-year survival rate of stage I, II, III and IV was 100%, 75%, 17.8% and 0, respectively (P < 0.05).
  • CONCLUSION: Remnant stomach cancer prevalently occurs in the male usually 10 years after Birroth II gastrectomy.
  • Poorly-differentiated adenocarcinoma is found to be the prevalent histological type of advanced remnant stomach cancer.
  • The prognosis of remnant stomach cancer is correlated with pTNM stage and whether having been treated with complete resection or not.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Gastric Stump / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416009.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Mlkvý P: Multimodal therapy of gastric cancer. Dig Dis; 2010;28(4-5):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of gastric cancer.
  • Adenocarcinoma of the stomach is the 2nd most common cancer worldwide.
  • The 5-year survival rates after curative surgical resection decline from 60-90% in stage I, to 30-50% in stage II and finally drop to only to 10-25% for patients in stage III of this disease.
  • According to certain criteria, early gastric cancer limited to the mucosa or submucosa is indicated for endoscopic mucosal resection.
  • In advanced gastric cancer with surgical approach, the questions of type of resection, extent of lymph node dissection and indication for splenectomy do arise.
  • Chemotherapy is the treatment of choice in stage IV for unresectable disease.
  • Survival rates in resectable gastric cancer are influenced mainly by the depth of invasion through the gastric wall and by the presence or absence of regional lymph node involvement.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088412.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


93. Al-Taie OH, Adam P, Kraus MR, Illert B, Scheurlen M: Giant fold gastritis with consecutive gastric carcinoma in a patient with peutz-jeghers syndrome. Z Gastroenterol; 2005 Jul;43(7):653-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant fold gastritis with consecutive gastric carcinoma in a patient with peutz-jeghers syndrome.
  • We describe the case of a 36-year-old patient with Peutz-Jeghers syndrome and a very unusual gastric morphology resembling giant fold gastritis.
  • Endoscopic ultrasound documented a hyperechoic widening of the gastric mucosa without involvement of the deeper layers.
  • However, despite annual control gastroscopies, an adenocarcinoma developed between the folds and was in an already advanced stage at diagnosis (UICC III).
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastritis, Hypertrophic / diagnosis. Peutz-Jeghers Syndrome / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Endosonography. Gastrectomy. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Gastroscopy. Helicobacter Infections / diagnosis. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001347.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Wang L, Li HG, Xia ZS, Lü J, Peng TS: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl); 2010 Dec;123(24):3554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.
  • BACKGROUND: Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is a newly identified mRNA-binding protein that is involved in embryogenesis and carcinogenesis of some malignant tumors.
  • The aim of this study was to detect the expression of IMP3 protein in gastric adenocarcinoma (GAC) and the correlation with clinicopathological features.
  • There was a significant TNM stage difference between GAC with and without IMP3 expression (P < 0.05).
  • Tumors with higher stage showed higher level of IMP3 expression.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. RNA-Binding Proteins / analysis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22166630.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Ki-67 Antigen; 0 / RNA-Binding Proteins
  •  go-up   go-down


95. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4309-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
  • PURPOSE: Epidermal growth factor receptor (EGFR) is highly expressed in some gastric cancers and is implicated in cancer cell growth and proliferation.
  • The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
  • METHODS: Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d).
  • CONCLUSION: Gefitinib reached the tumors at concentrations sufficient to inhibit EGFR activation in advanced gastric carcinoma patients, although this did not translate into clinical benefit.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]
  • (PMID = 16963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


96. Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol); 2005 Apr;17(2):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of second-line chemotherapy for advanced gastric adenocarcinoma.
  • Palliative chemotherapy has been shown to improve survival compared with best supportive care alone in patients with unresectable or recurrent gastric cancer.
  • At this stage, no standard second-line chemotherapy can be offered.
  • We review the published data concerning the use of second-line chemotherapy in gastric adenocarcinoma.
  • Response rates to second-line therapy in phase II trials are similar to those seen for other cancers that are more commonly retreated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Humans. Palliative Care. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830569.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


97. Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E, Spanish Cooperative Group for Digestive Tumor Therapy: Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1430-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
  • PURPOSE: To determine in a Phase II trial whether preoperative irinotecan-cisplatin (IC) followed by concurrent IC therapy and radiotherapy (IC/RT) improved outcome in patients with resectable, locally advanced gastric adenocarcinoma (GC) or esophagogastric junction cancer (EGJC).
  • PATIENTS AND METHODS: Patients with resectable Stage II-IV, M0 GC or EGJC made up the study population.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540072.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


98. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA: Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer; 2006 Oct 1;107(7):1475-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
  • BACKGROUND: Preoperative chemoradiation for localized gastric cancer can modify baseline stage, as determined by surgical pathology stage.
  • Therefore, the authors hypothesized that surgical pathology stage would be a better prognosticator of overall survival (OS) than baseline stage.
  • Patients must have had localized gastric adenocarcinoma and were staged extensively, including endoscopic ultrasonography and laparoscopy.
  • OS was correlated with pretreatment and posttreatment parameters, including surgical pathology stage according to American Joint Commission on Cancer criteria.
  • None of the pretreatment parameters correlated with OS; however, longer OS correlated with lower pathologic stage (P < .0001), R0 resection (P < .001), clinical response noted prior to surgery (P = .002), pathCR (P = .004), lower pathologic lymph node classification (P = .006), and lower pathologic tumor classification (P = .03).
  • Pathologic stage and R0 resection were independent prognostic factors for OS (multivariate Cox model; both P = .05).
  • CONCLUSIONS: When preoperative chemoradiation strategy was employed for gastric cancer, the surgical pathology stage, a reflection of cancer's biologic heterogeneity, was a better prognosticator of OS than the baseline clinical stage.
  • Surgical pathology stage, in this setting, may serve as an intermediate endpoint for Phase II/III trials.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16944539.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M: Transfusion alert for patients with curable cancer. World J Surg; 2007 Dec;31(12):2315-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Between January 1, 1990 and January 31, 2005, a total of 200 patients with proximal gastric cancer classified as having stage IB to III disease after curative resection were enrolled at Kitasato University Hospital in a retrospective manner, according to a previous report by Weitz et al.
  • A multivariate analysis including related factors revealed that POT was one of the most potent independent prognostic factors, as were stage and age.
  • Stratification analysis following the JCGC staging system revealed that the outstanding prognostic difference according to POT was recognized in patients anticipated to be cured, such as those with stage IB (p = 0.012) or II (p = 0.003) but not stage III.
  • SPL could dramatically improve the prognosis with POT in stage IB patients but modestly if at all in those with stage II or III.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Female. Humans. Male. Middle Aged. Multivariate Analysis. Perioperative Care. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):366-73 [12525531.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20 [12189224.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2606-17 [15452187.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2597-605 [15452188.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):573-80 [9554439.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):697-705 [12680170.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 6;97(7):489-98 [15812074.001]
  • [Cites] Lancet. 1994 Aug 27;344(8922):573-8 [7914960.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):5-12 [11829431.001]
  • [Cites] J Clin Oncol. 1985 May;3(5):698-709 [3998786.001]
  • [Cites] Am J Surg. 1994 Feb;167(2):256-60 [8135315.001]
  • [Cites] ANZ J Surg. 2004 Oct;74(10):852-4 [15456431.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1372-6 [8292113.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):681-2 [15721474.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1204-14 [11504766.001]
  • [Cites] Nat Med. 2000 Jan;6(1):100-2 [10613833.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1079-89 [16505427.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2290-7 [16710026.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):708-14 [16705125.001]
  • [Cites] J Surg Oncol. 1994 Mar;55(3):149-53 [8176923.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 15;84(2):98-103 [1735886.001]
  • [Cites] Ann Surg. 1993 Jul;218(1):47-53 [8328829.001]
  • [Cites] J Natl Cancer Inst. 1993 May 19;85(10):801-6 [8487324.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4597-603 [14673048.001]
  • (PMID = 17917774.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Jhawer M, Coit D, Brennan M, Qin LX, Gonen M, Klimstra D, Tang L, Kelsen DP, Shah MA: Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation. Am J Clin Oncol; 2009 Aug;32(4):356-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
  • BACKGROUND: We examined gene expression profiles and clinicopathologic features (tumor location, stage, graded pathologic response, perineural invasion (PNI), Lauren's classification, and survival) of patients with gastric cancer who received preoperative chemotherapy to identify prognostic markers.
  • METHODS: Thirty-eight patients with locally advanced gastric cancer received preoperative chemotherapy on a phase II trial.
  • The close association between PNI and overall survival was identified and validated immunohistochemically in 31 completely resected gastric tumors.
  • PNI added significant prognostic value to posttreatment pathologic stage, (P < 0.01).
  • The presence of PNI provides additional prognostic importance to posttreatment pathologic stage and may indicate treatment resistance.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Peripheral Nervous System Neoplasms / mortality. Peripheral Nervous System Neoplasms / therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381079.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA56225
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement